SENATE BILL NO. 161–SENATORS SCHEIBLE, D. HARRIS, SPEARMAN, CANNIZZARO, SEEVERS GANSERT; DALY, DONATE, DONDERO LOOP, FLORES, GOICOECHEA, HANSEN, KRASNER, NEAL, NGUYEN, OHRENSCHALL, PAZINA AND STONE

FEBRUARY 15, 2023

Referred to Committee on Health and Human Services

SUMMARY—Makes revisions relating to personal health and wellness. (BDR 38-811)

FISCAL NOTE: Effect on Local Government: No. Effect on the State: Yes.

> CONTAINS UNFUNDED MANDATE (§ 15 & NRS 287.010) (NOT REQUESTED BY AFFECTED LOCAL GOVERNMENT)

EXPLANATION - Matter in *bolded italics* is new; matter between brackets [omitted material] is material to be omitted.

AN ACT relating to personal health; expanding required insurance coverage of contraception; providing for the use of benefits under certain federal programs for persons with low incomes to purchase menstrual products; authorizing the establishment of a program to assist certain recipients of public assistance in the purchase of menstrual products; authorizing certain persons and entities to acquire controlled substances and dangerous drugs directly from an outsourcing facility; revising requirements governing the dispensing of a drug used for contraception; enacting the Interstate Massage Compact; increasing the number of members of the Board of Massage Therapy required to constitute a quorum for the purposes of transacting the business of the Board; clarifying that a pharmacy benefit manager is subject to certain provisions of law governing an insurer for which the pharmacy benefit manager manages prescription drug coverage; and providing other matters properly relating thereto.





#### Legislative Counsel's Digest:

1 Existing law requires public and private policies of insurance regulated under 234567 Nevada law to include coverage for up to a 12-month supply of contraceptive drugs. (NRS 287.010, 287.04335, 422.27172, 689A.0418, 689B.0378, 689C.1676, 695A.1865, 695B.1919, 695C.1696, 695G.1715) Sections 1, 11 and 14-20 of this bill prohibit an insurer from requiring an insured to obtain prior authorization before receiving a contraceptive drug. Sections 1 and 14-20 also require an insurer to: (1) cover certain contraceptive services when provided by a pharmacist to the 8 same extent as if the services were provided by another provider of health care in 9 certain circumstances; and (2) reimburse a pharmacist for providing such services 10 at a rate that is not less than the rate provided to a physician, physician assistant or 11 advanced practice registered nurse. Sections 1 and 14-20 additionally prescribe 12 13 certain limitations on the imposition of a copayment or coinsurance for a drug for contraception. Section 10 of this bill requires an insurer to: (1) demonstrate the 14 capacity to adequately deliver family planning services provided by pharmacists to 15 covered persons; and (2) make available to covered persons a notice of pharmacists 16 and pharmacies that are available to provide family planning services to covered 17 persons through the network of the insurer. Sections 12 and 13 of this bill make 18 conforming changes to indicate the proper placement of section 10 in the Nevada 19 Revised Statutes.

Existing law imposes certain duties on a pharmacy benefit manager. (NRS
683A.178) Section 9 of this bill clarifies that a pharmacy benefit manager that
manages prescription drug benefits for an insurer is required to comply with the
same provisions of the Nevada Insurance Code as are applicable to the insurer.
Existing law authorizes the Department of Health and Human Services to enter
into a contract with a pharmacy benefit manager or a health maintenance

Existing law authorizes the Department of Health and Human Services to enter into a contract with a pharmacy benefit manager or a health maintenance organization to manage, direct and coordinate all payments and rebates for prescription drugs and all other services and payments relating to the provision of prescription drugs under the State Plan for Medicaid and the Children's Health Insurance Program. (NRS 422.4053) **Section 2** of this bill requires such a contract to require the pharmacy benefit manager or health maintenance organization to comply with certain provisions of law regarding the provision of prescription drugs under the State Plan for Medicaid and the Children's Health Insurance Program. Existing federal law establishes the Supplemental Nutrition Assistance

Existing federal law establishes the Supplemental Nutrition Assistance 34 Program, which provides assistance to certain low-income families for the purchase 35 of food. (7 U.S.C. §§ 2011 et seq.) Existing federal law also establishes the Special 36 Supplemental Nutrition Program for Women, Infants and Children, which provides, 37 through eligible local agencies, nutrition education and supplemental foods to 38 pregnant women, mothers, infants and children less than 5 years of age with low 39 household incomes. (42 U.S.C. § 1786) Existing law requires the Department of 40 Health and Human Services to administer these programs within this State. (NRS 41 422A.338) Section 3 of this bill requires the Department to authorize recipients of 42 benefits provided under those programs to use such benefits to purchase menstrual 43 products: (1) to the extent authorized by federal law; and (2) to the extent that 44 federal funding is available. This bill also authorizes the Department to: (1) 45 establish and administer a program to provide assistance for the purpose of 46 purchasing menstrual products to recipients of benefits provided through programs 47 for which the Division of Welfare and Supportive Services of the Department is 48 responsible; and (2) accept gifts, grants and donations for the purposes of 49 establishing such a program.

50 Existing law imposes certain requirements governing the purchase and sale of 51 controlled substances and dangerous drugs. (NRS 639.268) Existing regulations 52 prescribe certain requirements concerning the operation of outsourcing facilities, 53 which are federally registered facilities that engage in the compounding of drugs. 54 (NAC 639.691-639.6916) Those requirements include requirements that an





55 outsourcing facility: (1) be licensed by the State Board of Pharmacy as a 56 manufacturer; and (2) comply with regulatory requirements governing 57 manufacturers. (NAC 639.6915) Section 5 of this bill authorizes a person or entity 58 authorized to dispense controlled substances and dangerous drugs to purchase or 59 otherwise acquire controlled substances and dangerous drugs compounded or 60 repackaged by an outsourcing facility directly from the outsourcing facility. 61 **Section 4** of this bill makes a conforming change to update an internal reference 62 changed by section 5.

63 Existing law requires a pharmacist to dispense up to a 12-month supply of 64 contraceptives or therapeutic equivalent or any amount which covers the remainder 65 of the plan year, whichever is less, pursuant to a valid prescription or order if: (1) 66 the patient has previously received a 3-month supply of the same drug; (2) the 67 patient has previously received a 9-month supply of the same drug or a supply of 68 the same drug for the balance of the plan year in which the 3-month supply was 69 prescribed or ordered, whichever is less; (3) the patient is insured by the same 70 health insurance plan; and (4) a provider of health care has not specified in the 71 prescription or order that a different supply of the drug is necessary. (NRS 72 639.28075) If a patient is not currently using a contraceptive or therapeutic ź3 equivalent, section 6 of this bill requires a pharmacist to dispense a full 3-month 74 supply or the amount designated by the prescription or order, whichever is less, 75 pursuant to a valid prescription or order unless the patient is unable or unwilling to 76 pay the applicable charge, copayment or coinsurance. If the patient is currently 77 using the contraceptive or therapeutic equivalent, section 6 requires a pharmacist to 78 dispense a full 9-month supply or a full 12-month supply, as applicable, any 79 amount designated by the prescription or order or any amount which covers the 80 remainder of the plan year, whichever is less, pursuant to a valid prescription or 81 order unless the patient is unable or unwilling to pay the applicable charge, 82 copayment or coinsurance.

Existing law authorizes the Board of Massage Therapy to issue a license to practice massage therapy and sets forth the requirements that an applicant for a license must satisfy in order to become licensed. (NRS 640C.580) Section 7 of this bill adopts the Interstate Massage Compact, creating a multistate license with uniform licensing requirements, including a national licensing examination, for use by licensees in all member states.

89 The Compact requires that, in order to be eligible to join the Compact and 90 maintain eligibility as a member state, a state must: (1) license and regulate the 91 practice of massage therapy; (2) have a mechanism or entity in place to receive and 92 investigate complaints from the public, regulatory or law enforcement agencies or 93 the Interstate Massage Compact Commission about licensees practicing in that 94 state; (3) accept passage of a national licensing examination as a criterion for 95 massage therapy licensure in that state; (4) require that licensees satisfy educational 96 requirements before being licensed; (5) implement procedures for requiring 97 background checks for a multistate license and other reporting requirements; (6) 98 have continuing competence requirements; (7) participate in the Compact's data 99 system; (8) notify the Commission and other member states of any disciplinary 100 action taken against a licensee practicing under a multistate license; (9) comply 101 with any rules of the Commission; and (10) accept licensees with valid multistate 102 licenses from other member states. An applicant for a multistate license must: (1) 103 hold a license to practice massage therapy in a member state; (2) complete 625 104 hours of massage therapy education or the substantial equivalent; (3) pass a 105 national licensing examination or the substantial equivalent; (4) submit to and pass 106 a background check; and (5) pay all required fees.

107 The Compact: (1) establishes the Interstate Massage Compact Commission as a 108 joint governmental agency whose membership consists of all member states; and 109 (2) provides for the Commission's rules and governance. The Compact also





establishes a data system, provided for by the Commission, and requires memberstates to submit uniform data to the data system on all individuals to whom theCompact is applicable.

113 The Compact provides additional provisions to carry out the Compact, 114 including providing procedures for the taking of adverse actions against licensees, 115 provisions for active military members or their spouses, provisions for rulemaking 116 by the Commission, provisions for oversight and dispute resolution and procedures 117 for amendments and withdrawals. The Compact takes effect on the date on which 118 the Compact is enacted into law by the seventh member state.

Existing law provides that four members of the Board of Massage Therapy constitute a quorum for the purposes of transacting the business of the Board. (NRS 640C.180) Section 8 of this bill increases the number of board members needed to constitute a quorum from four to five.

# THE PEOPLE OF THE STATE OF NEVADA, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

1 **Section 1.** NRS 422.27172 is hereby amended to read as 2 follows:

422.27172 1. The Director shall include in the State Plan for
 Medicaid a requirement that the State pay the nonfederal share of
 expenditures incurred for:

6 (a) Up to a 12-month supply, per prescription, of any type of 7 drug for contraception or its therapeutic equivalent which is:

(1) Lawfully prescribed or ordered;

(g) Voluntary sterilization for women.

8 9 10

(2) Approved by the Food and Drug Administration; and

(3) Dispensed in accordance with NRS 639.28075;

(b) Any type of device for contraception which is lawfully
prescribed or ordered and which has been approved by the Food and
Drug Administration;

(c) Self-administered hormonal contraceptives dispensed by a
 pharmacist pursuant to NRS 639.28078;

16 (d) Insertion or removal of a device for contraception;

(e) Education and counseling relating to the initiation of the use
of contraceptives and any necessary follow-up after initiating such
use;

20 (f) Management of side effects relating to contraception; and

21

22 2. Except as otherwise provided in subsections 4 and 5, to 23 obtain any benefit provided in the Plan pursuant to subsection 1, a 24 person enrolled in Medicaid must not be required to:

25 26 (a) Pay a higher deductible, any copayment or coinsurance; or

(b) Be subject to a longer waiting period or any other condition.

3. The Director shall ensure that the provisions of this section are carried out in a manner which complies with the requirements established by the Drug Use Review Board and set forth in the list





of preferred prescription drugs established by the Department 1 2 pursuant to NRS 422.4025.

3 The Plan may require a person enrolled in Medicaid to pay a 4. higher deductible, copayment or coinsurance for a drug for 4 5 contraception if the person refuses to accept a therapeutic equivalent 6 of the contraceptive drug.

7 For each method of contraception which is approved by the 5. 8 Food and Drug Administration, the Plan must include at least one 9 contraceptive drug or device for which no deductible, copayment or 10 coinsurance may be charged to the person enrolled in Medicaid, but 11 the Plan may charge a deductible, copayment or coinsurance for any 12 other contraceptive drug or device that provides the same method of 13 contraception. If the Plan requires a person enrolled in Medicaid to pay a copayment or coinsurance for a drug for contraception, 14 15 the Plan may only require the person to pay the copayment or 16 coinsurance:

17 (a) Once for the entire amount of the drug dispensed for the 18 plan year; or

19

(b) Once for each 1-month supply of the drug dispensed.

The Plan must provide for the reimbursement of a 20 6. pharmacist for providing services described in subsection 1 that 21 are within the scope of practice of the pharmacist to the same 22 23 extent as if the services were provided by another provider of 24 health care. The Plan must not limit:

25 (a) Coverage for such services provided by a pharmacist to a 26 number of occasions less than the coverage for such services when 27 provided by another provider of health care.

28 (b) Reimbursement for such services provided by a pharmacist 29 to an amount less than the amount reimbursed for similar services 30 provided by a physician, physician assistant or advanced practice registered nurse. 31

The Plan must not require a recipient of Medicaid to 32 7. 33 obtain prior authorization for the benefits described in paragraphs (a) and (c) of subsection 1. 34 35

8. As used in this section:

(a) "Drug Use Review Board" has the meaning ascribed to it in 36 NRS 422.402. 37

38 (b) "Provider of health care" has the meaning ascribed to it in 39 NRS 629.031.

40 (c) "Therapeutic equivalent" means a drug which:

(1) Contains an identical amount of the same active 41 42 ingredients in the same dosage and method of administration as 43 another drug;





1 (2) Is expected to have the same clinical effect when 2 administered to a patient pursuant to a prescription or order as 3 another drug; and

4 (3) Meets any other criteria required by the Food and Drug 5 Administration for classification as a therapeutic equivalent.

6

Sec. 2. NRS 422.4053 is hereby amended to read as follows:

7 422.4053 1. Except as otherwise provided in subsection 2, 8 the Department shall directly manage, direct and coordinate all 9 payments and rebates for prescription drugs and all other services 10 and payments relating to the provision of prescription drugs under 11 the State Plan for Medicaid and the Children's Health Insurance 12 Program.

13 2. The Department may enter into a contract with:

14 (a) A pharmacy benefit manager for the provision of any 15 services described in subsection 1.

16 (b) A health maintenance organization pursuant to NRS 422.273 17 for the provision of any of the services described in subsection 1 for 18 recipients of Medicaid or recipients of insurance through the 19 Children's Health Insurance Program who receive coverage through 20 a Medicaid managed care program.

(c) One or more public or private entities from this State, the
 District of Columbia or other states or territories of the United States
 for the collaborative purchasing of prescription drugs in accordance
 with subsection 3 of NRS 277.110.

25 3. A contract entered into pursuant to paragraph (a) or (b) of 26 subsection 2 must:

27

(a) Include the provisions required by NRS 422.4056; [and]

28 (b) Require the pharmacy benefit manager or health 29 maintenance organization, as applicable, to disclose to the 30 Department any information relating to the services covered by the 31 contract, including, without limitation, information concerning 32 dispensing fees, measures for the control of costs, rebates collected 33 and paid and any fees and charges imposed by the pharmacy benefit 34 manager or health maintenance organization pursuant to the contract 35 [-]; and

(c) Require the pharmacy benefit manager or health
maintenance organization to comply with the provisions of this
chapter regarding the provision of prescription drugs under the
State Plan for Medicaid and the Children's Health Insurance
Program to the same extent as the Department.

41 4. In addition to meeting the requirements of subsection 3, a 42 contract entered into pursuant to:

(a) Paragraph (a) of subsection 2 may require the pharmacy
benefit manager to provide the entire amount of any rebates
received for the purchase of prescription drugs, including, without





limitation, rebates for the purchase of prescription drugs by an entity
 other than the Department, to the Department.

(b) Paragraph (b) of subsection 2 must require the health 3 maintenance organization to provide to the Department the entire 4 5 amount of any rebates received for the purchase of prescription 6 drugs, including, without limitation, rebates for the purchase of 7 prescription drugs by an entity other than the Department, less an administrative fee in an amount prescribed by the contract. The 8 9 Department shall adopt policies prescribing the maximum amount 10 of such an administrative fee.

11 **Sec. 3.** Chapter 422A of NRS is hereby amended by adding 12 thereto a new section to read as follows:

13 1. To the extent authorized by federal law and to the extent 14 that federal funding is available, the Department shall authorize 15 recipients of benefits provided under Supplemental Nutrition 16 Assistance or the Special Supplemental Nutrition Program for 17 Women, Infants and Children established by 42 U.S.C. § 1786 to 18 use such benefits to purchase menstrual products.

19 2. The Department shall take any action necessary to obtain 20 federal authorization and federal funding to carry out the 21 provisions of subsection 1, including, without limitation, applying 22 for any necessary federal waiver.

3. To the extent that money is available for this purpose, the Department, through the Division, may establish and administer a program to provide assistance for the purpose of purchasing menstrual products to recipients of benefits provided through programs for which the Division is responsible. The Department may accept gifts, grants and donations from any source for the purpose of establishing and administering such a program.

30 4. As used in this section, "menstrual products" includes, 31 without limitation, sanitary napkins, tampons or similar products 32 used in connection with the menstrual cycle.

Sec. 4. NRS 454.221 is hereby amended to read as follows:

454.221 1. A person who furnishes any dangerous drug
except upon the prescription of a practitioner is guilty of a category
D felony and shall be punished as provided in NRS 193.130, unless
the dangerous drug was obtained originally by a legal prescription.

38 2. The provisions of this section do not apply to the furnishing39 of any dangerous drug by:

40 (a) A practitioner to his or her patients;

(b) A physician assistant licensed pursuant to chapter 630 or 633
of NRS if authorized by the Board;

43 (c) A registered nurse while participating in a public health 44 program approved by the Board, or an advanced practice registered





nurse who holds a certificate from the State Board of Pharmacy
 permitting him or her to dispense dangerous drugs;

3 (d) A manufacturer or wholesaler or pharmacy to each other or 4 to a practitioner or to a laboratory under records of sales and 5 purchases that correctly give the date, the names and addresses of 6 the supplier and the buyer, the drug and its quantity;

(e) A hospital pharmacy or a pharmacy so designated by a 7 8 county health officer in a county whose population is 100,000 or more, or by a district health officer in any county within its 9 jurisdiction or, in the absence of either, by the Chief Medical Officer 10 or the Chief Medical Officer's designated Medical Director of 11 12 Emergency Medical Services, to a person or agency described in 13 subsection 3 4 of NRS 639.268 to stock ambulances or other 14 authorized vehicles or replenish the stock; or

15 (f) A pharmacy in a correctional institution to a person 16 designated by the Director of the Department of Corrections to 17 administer a lethal injection to a person who has been sentenced to 18 death.

19

**Sec. 5.** NRS 639.268 is hereby amended to read as follows:

20 639.268 1. A practitioner may purchase supplies of 21 controlled substances, poisons, dangerous drugs and devices from a 22 pharmacy by:

(a) Making an oral order to the pharmacy or transmitting an oral
 order through his or her agent, except an order for a controlled
 substance in schedule II; or

(b) If the order is for a controlled substance, presenting to the
pharmacy a written order signed by the practitioner which contains
his or her registration number issued by the Drug Enforcement
Administration.

30 2. Any person or entity authorized to dispense controlled 31 substances and dangerous drugs, including, without limitation, a 32 pharmacy, institutional pharmacy or practitioner, may:

(a) Purchase or otherwise acquire controlled substances and
 dangerous drugs compounded or repackaged by an outsourcing
 facility directly from the outsourcing facility without an order
 from a practitioner other than, where applicable, the practitioner
 purchasing or acquiring the controlled substance or dangerous
 drug; and

(b) Administer and dispense controlled substances and
dangerous drugs purchased or acquired pursuant to paragraph (a)
to the same extent as controlled substances and dangerous drugs
acquired through other authorized means.

A hospital pharmacy or a pharmacy designated for this
purpose by a county health officer in a county whose population is
100,000 or more, or by a district health officer in any county within





1 its jurisdiction or, in the absence of either, by the Chief Medical
2 Officer or his or her designated medical director of emergency
3 medical services, may sell to a person or agency described in
4 supplies of controlled substances to stock the
5 ambulances or other authorized vehicles of such a person or agency
6 or replenish the stock if:

7 (a) The person or agency is registered with the Drug 8 Enforcement Administration pursuant to 21 C.F.R. Part 1301;

9

(b) The person in charge of the controlled substances is:

10 (1) A paramedic appropriately certified by the health 11 authority;

12 (2) A registered nurse licensed by the State Board of 13 Nursing; or

14 (3) A person who holds equivalent certification or licensure 15 issued by another state; and

16 (c) Except as otherwise provided in this paragraph, the purchase 17 order is countersigned by a physician or initiated by an oral order 18 and may be made by the person or agency or transmitted by an agent 19 of such a person or agency. An order for a controlled substance 20 listed in schedule II must be made pursuant to NRS 453.251.

21 [3.] 4. A pharmacy, institutional pharmacy or other person 22 licensed by the Board to furnish controlled substances and 23 dangerous drugs may sell to:

(a) The holder of a permit issued pursuant to the provisions of
 NRS 450B.200 or 450B.210;

(b) The holder of a permit issued by another state which is
substantially similar to a permit issued pursuant to the provisions of
NRS 450B.200 or 450B.210; and

(c) An agency of the Federal Government that provides
emergency care or transportation and is registered with the Drug
Enforcement Administration pursuant to 21 C.F.R. Part 1301.

[4.] 5. A pharmacy, institutional pharmacy , *outsourcing facility* or other person licensed by the Board to furnish dangerous
 drugs who sells supplies pursuant to this section shall maintain a
 record of each sale which must contain:

36 (a) The date of sale;

(b) The name, address and signature of the purchaser or theperson receiving the delivery;

39 (c) The name of the dispensing pharmacist [;], where 40 applicable;

41 (d) The name and address of the authorizing practitioner [;], 42 *where applicable;* and

43 (e) The name, strength and quantity of each drug sold.

44 **[5.]** 6. A pharmacy, institutional pharmacy or other person 45 licensed by the Board to furnish dangerous drugs who supplies the





1 initial stock for an ambulance or other emergency vehicle shall 2 comply with any applicable regulations adopted by the State Board 3 of Health, or a district board of health, pursuant to NRS 450B.120.

4 The Board shall adopt regulations regarding the records <del>6.]</del> 7. 5 a pharmacist shall keep of any purchase made pursuant to this 6 section. 7

As used in this section: **8**.

8 (a) "Compounding" includes, without limitation. the combining, admixing, mixing, pooling, reconstituting or other 9 altering of a drug or bulk drug substance, as defined in 21 C.F.R. 10 11 § 207.3, to create a drug.

(b) "Outsourcing facility" means a manufacturer at one 12 13 geographic location or address that:

14 (1) Is engaged in the compounding of sterile or nonsterile 15 drugs for use by humans; and

(2) Has registered with the Secretary of Health and Human 16 17 Services as an outsourcing facility pursuant to 21 U.S.C. § 353b.

**Sec. 6.** NRS 639.28075 is hereby amended to read as follows:

19 639.28075 1. Except as otherwise provided in [subsections] subsection 2, [and 3,] pursuant to a valid prescription or order for a 20 21 drug to be used for contraception or its therapeutic equivalent which 22 has been approved by the Food and Drug Administration, a 23 pharmacist shall:

24 (a) [The first time dispensing the drug or therapeutic equivalent 25 to If the patient is not currently using the drug or its 26 *therapeutic equivalent*, dispense up to a 3-month supply of the drug 27 or therapeutic equivalent [] or any amount designated by the 28 prescription or order, whichever is less.

29 (b) [The second time dispensing] If the drug or therapeutic equivalent has only been dispensed to the patient [,] once pursuant 30 to paragraph (a), dispense up to a 9-month supply of the drug or 31 32 therapeutic equivalent, any amount designated by the prescription 33 *or order* or any amount which covers the remainder of the plan year 34 if the patient is covered by a health care plan, whichever is less.

35 (c) For a refill in a plan year following the initial dispensing of a 36 drug or therapeutic equivalent pursuant to paragraphs (a) and (b), 37 dispense [up to] a 12-month supply of the drug or therapeutic 38 equivalent, any amount designated by the prescription or order or 39 any amount which covers the remainder of the plan year if the patient is covered by a health care plan, whichever is less. 40

41 The provisions of paragraphs (b) and (c) of subsection 1 2. 42 only apply if:

43 (a) The drug for contraception or the therapeutic equivalent of 44 such drug is the same drug or therapeutic equivalent which was





1 previously prescribed or ordered pursuant to paragraph (a) of

2 subsection 1: and

(b) The patient is covered by the same health care plan. 3

4 <u>3. If a prescription or order for a drug for contraception or its</u>

5 therapeutic equivalent limits the dispensing of the drug or

6 therapeutic equivalent to a quantity which is less than the amount

otherwise authorized to be dispensed pursuant to subsection 1, the 7

8 pharmacist must dispense the drug or therapeutic equivalent in

accordance with the quantity specified in the prescription or order. 9

-4.] A pharmacist is not required to dispense an amount of a 10 drug to be used for contraception or its therapeutic equivalent for 11 which the patient is unable or unwilling to pay any applicable 12 13 charge, copayment or coinsurance due to the pharmacy.

14

34

35 36 *3*. As used in this section:

15 (a) "Health care plan" means a policy, contract, certificate or 16 agreement offered or issued by an insurer, including without 17 limitation, the State Plan for Medicaid, to provide, deliver, arrange 18 for, pay for or reimburse any of the costs of health care services.

19 (b) "Plan year" means the year designated in the evidence of 20 coverage of a health care plan in which a person is covered by such 21 plan. 22

(c) "Therapeutic equivalent" means a drug which:

23 (1) Contains an identical amount of the same active 24 ingredients in the same dosage and method of administration as 25 another drug;

26 (2) Is expected to have the same clinical effect when 27 administered to a patient pursuant to a prescription or order as 28 another drug; and

29 (3) Meets any other criteria required by the Food and Drug 30 Administration for classification as a therapeutic equivalent.

Sec. 7. Chapter 640C of NRS is hereby amended by adding 31 32 thereto a new section to read as follows: 33

### **INTERSTATE MASSAGE COMPACT ARTICLE 1-PURPOSE**

37 The purpose of this Compact is to reduce the burdens on State 38 governments and to facilitate the interstate practice and regulation of Massage Therapy with the goal of improving public access to, 39 and the safety of, Massage Therapy Services. Through this 40 Compact, the Member States seek to establish a regulatory 41 42 framework which provides for a new multistate licensing program. Through this additional licensing pathway, the Member States 43 44 seek to provide increased value and mobility to licensed massage





therapists in the Member States, while ensuring the provision of

1 2 safe, competent, and reliable services to the public.

3 This Compact is designed to achieve the following objectives, and the Member States hereby ratify the same intentions by 4 5 subscribing hereto:

6 A. Increase public access to Massage Therapy Services by 7 providing for a multistate licensing pathway:

8 **B.** Enhance the Member States' ability to protect the public's 9 *health and safety;* 

10 Enhance the Member States' ability to prevent human С. trafficking and licensure fraud: 11

12 Encourage the cooperation of Member States in **D**. regulating the multistate Practice of Massage Therapy; 13 14

Support relocating military members and their spouses; *E*.

Facilitate and enhance the exchange of licensure, 15 F. investigative, and disciplinary information between the Member 16 17 States;

18 **G**. Create an Interstate Commission that will exist to *implement and administer the Compact;* 19

20 H. Allow a Member State to hold a Licensee accountable, 21 even where that Licensee holds a Multistate License:

Create a streamlined pathway for Licensees to practice in 22 Ι. 23 Member States, thus increasing the mobility of duly licensed 24 massage therapists: and

J. Serve the needs of licensed massage therapists and the 25 26 public receiving their services; however,

27 *K*. Nothing in this Compact is intended to prevent a State 28 from enforcing its own laws regarding the Practice of Massage 29 Therapy. 30

**ARTICLE 2-DEFINITIONS** 

31 32

As used in this Compact, except as otherwise provided and 33 subject to clarification by the Rules of the Commission, the 34 35 following definitions shall govern the terms herein:

*"Active Military Member" - any person with full-time duty* 36 **A**. status in the armed forces of the United States, including members 37 of the National Guard and Reserve. 38

"Adverse Action" - any administrative, civil, equitable, or 39 **B**. criminal action permitted by a Member State's laws which is 40 imposed by a Licensing Authority or other regulatory body against 41 42 Licensee. including actions against an individual's a 43 Authorization to Practice such as revocation, suspension, probation, surrender in lieu of discipline, monitoring of the 44 45 Licensee, limitation of the Licensee's practice, or any other



1 Encumbrance on licensure affecting an individual's ability to 2 practice Massage Therapy, including the issuance of a cease and 3 desist order.

4 C. "Alternative Program" - a non-disciplinary monitoring or 5 prosecutorial diversion program approved by a Member State's 6 Licensing Authority.

7 D. "Authorization to Practice" - a legal authorization by a 8 Remote State pursuant to a Multistate License permitting the 9 Practice of Massage Therapy in that Remote State, which shall be 10 subject to the enforcement jurisdiction of the Licensing Authority 11 in that Remote State.

12 E. "Background Check" - the submission of an applicant's 13 criminal history record information, as further defined in 28 14 C.F.R. § 20.3(d), as amended from the Federal Bureau of 15 Investigation and the agency responsible for retaining State 16 criminal records in the applicant's Home State.

"Charter Member States" - Member States who have 17 **F**. enacted legislation to adopt this Compact where such legislation 18 predates the effective date of this Compact as defined in Article 12. 19 "Commission" -20 *G*. the government agency whose 21 membership consists of all States that have enacted this Compact, 22 which is known as the Interstate Massage Compact Commission, 23 as defined in Article 8, and which shall operate as an 24 instrumentality of the Member States.

H. "Continuing Competence" - a requirement, as a condition
of license renewal, to provide evidence of participation in, and
completion of, educational or professional activities that maintain,
improve, or enhance Massage Therapy fitness to practice.

29 *I*. *"Current* Significant Investigative Information" Investigative Information that a Licensing Authority, after an 30 inquiry or investigation that complies with a Member State's due 31 32 process requirements, has reason to believe is not groundless and, 33 if proved true, would indicate a violation of that State's laws regarding the Practice of Massage Therapy. 34

35 J. "Data System" - a repository of information about 36 Licensees who hold Multistate Licenses, which may include but is 37 not limited to license status, Investigative Information, and 38 Adverse Actions.

39 K. "Disqualifying Event" - any event which shall disqualify 40 an individual from holding a Multistate License under this 41 Compact, which the Commission may by Rule specify.

42 L. "Encumbrance" - a revocation or suspension of, or any 43 limitation or condition on, the full and unrestricted Practice of 44 Massage Therapy by a Licensing Authority.





1 *M. "Executive Committee" - a group of delegates elected or* 2 appointed to act on behalf of, and within the powers granted to 3 them by, the Commission.

4 N. "Home State" - means the Member State which is a 5 Licensee's primary state of residence where the Licensee holds an 6 active Single-State License.

7 O. "Investigative Information" - information, records, or 8 documents received or generated by a Licensing Authority 9 pursuant to an investigation or other inquiry.

10 P. "Licensing Authority" - a State's regulatory body 11 responsible for issuing Massage Therapy licenses or otherwise 12 overseeing the Practice of Massage Therapy in that State.

13 Q. "Licensee" - an individual who currently holds a license 14 from a Member State to fully practice Massage Therapy, whose 15 license is not a student, provisional, temporary, inactive, or other 16 similar status.

*R. "Massage Therapy", "Massage Therapy Services", and the "Practice of Massage Therapy" - the care and services provided by a Licensee as set forth in the Member State's statutes and regulations in the State where the services are being provided. S. "Member State" - any State that has adopted this Compact.*

S. "Member State" - any State that has adopted this Compact.
 T. "Multistate License" - a license that consists of

Authorizations to Practice Massage Therapy in all Remote States pursuant to this Compact, which shall be subject to the enforcement jurisdiction of the Licensing Authority in a Licensee's Home State.

27 U. "National Licensing Examination" - A national 28 examination developed by a national association of Massage 29 Therapy regulatory boards, as defined by Commission Rule, that is derived from a practice analysis and is consistent with generally 30 accepted psychometric principles of fairness, validity and 31 reliability, and is administered under secure and confidential 32 33 examination protocols.

34 V. "Remote State" - any Member State, other than the 35 Licensee's Home State.

36 W. "Rule" - any opinion or regulation promulgated by the 37 Commission under this Compact, which shall have the force of 38 law.

39 X. "Single-State License" - a current, valid authorization 40 issued by a Member State's Licensing Authority allowing an 41 individual to fully practice Massage Therapy, that is not a 42 restricted, student, provisional, temporary, or inactive practice 43 authorization and authorizes practice only within the issuing 44 State.





3 4 **ARTICLE 3-MEMBER STATE REOUIREMENTS** 5 6 To be eligible to join this Compact, and to maintain Α. 7 eligibility as a Member State, a State must: 8 1. License and regulate the Practice of Massage Therapy; 2. 9 Have a mechanism or entity in place to receive and investigate complaints from the public, regulatory or law 10 enforcement agencies, or the Commission about Licensees 11 12 practicing in that State: 13 3. Accept passage of a National Licensing Examination as a 14 criterion for Massage Therapy licensure in that State; Require that Licensees satisfy educational requirements 15 4. prior to being licensed to provide Massage Therapy Services to the 16 17 *public in that State;* Implement procedures for requiring the Background 18 5. Check of applicants for a Multistate License, and for the reporting 19 20 of any Disqualifying Events, including but not limited to obtaining 21 and submitting, for each Licensee holding a Multistate License and each applicant for a Multistate License, fingerprint or other 22 23 biometric-based information to the Federal Bureau of 24 Investigation for Background Checks: receiving the results of the Federal Bureau of Investigation record search on Background

Federal Bureau of Investigation record search on Background
Checks and considering the results of such a Background Check
in making licensure decisions;

6. Have Continuing Competence requirements as a condition
for license renewal;

7. Participate in the Data System, including through the use
of unique identifying numbers as described herein;

8. Notify the Commission and other Member States, in compliance with the terms of the Compact and Rules of the Commission, of any disciplinary action taken by the State against a Licensee practicing under a Multistate License in that State, or of the existence of Investigative Information or Current Significant Investigative Information regarding a Licensee practicing in that State pursuant to a Multistate License;

39 9. Comply with the Rules of the Commission;

40 10. Accept Licensees with valid Multistate Licenses from 41 other Member States as established herein;

42 B. Individuals not residing in a Member State shall continue 43 to be able to apply for a Member State's Single-State License as 44 provided under the laws of each Member State. However, the 45 Single-State License granted to those individuals shall not be



1

2

**Y**.

or the District of Columbia.



"State" - a state, territory, possession of the United States,

– 16 –

C. Nothing in this Compact shall affect the requirements

recognized as granting a Multistate License for Massage Therapy

established by a Member State for the issuance of a Single-State

5 License: and 6 D. A Multistate License issued to a Licensee shall be 7 recognized by each Remote State as an Authorization to Practice 8 Massage Therapy in each Remote State. 9 10 **ARTICLE 4-MULTISTATE LICENSE REOUIREMENTS** 11 12 To qualify for a Multistate License under this Compact, **A**. 13 and to maintain eligibility for such a license, an applicant must: 14 1. Hold an active Single-State License to practice Massage Therapy in the applicant's Home State; 15 2. Have completed at least six hundred and twenty-five (625) 16 clock hours of Massage Therapy education or the substantial 17 equivalent which the Commission may approve by Rule. 18 3. Have passed a National Licensing Examination or the 19 20 substantial equivalent which the Commission may approve by 21 **Rule**: 22 Submit to a Background Check; 4. 23 5. Have not been convicted or found guilty, or have entered 24 into an agreed disposition, of a felony offense under applicable State or federal criminal law, within five (5) years prior to the date 25 26 of their application, where such a time period shall not include 27 any time served for the offense, and provided that the applicant 28 has completed any and all requirements arising as a result of any 29 such offense; 6. Have not been convicted or found guilty, or have entered 30 into an agreed disposition, of a misdemeanor offense related to the 31 32 **Practice** of Massage Therapy under applicable State or federal criminal law, within two (2) years prior to the date of their 33 application where such a time period shall not include any time 34 served for the offense, and provided that the applicant has 35 completed any and all requirements arising as a result of any such 36 offense; 37 Have not been convicted or found guilty, or have entered 38 7. into an agreed disposition, of any offense, whether a misdemeanor 39 or a felony, under State or federal law, at any time, relating to any 40 41 of the following: 42 a. Kidnapping; 43 b. Human trafficking: 44 c. Human smuggling; d. Sexual battery, sexual assault, or any related offenses; or 45



1 2

3

4

in any other Member State:



1 e. Any other category of offense which the Commission 2 may by Rule designate.

8. Have not previously held a Massage Therapy license which was revoked by, or surrendered in lieu of discipline to an pplicable Licensing Authority;

6 9. Have no history of any Adverse Action on any 7 occupational or professional license within two (2) years prior to 8 the date of their application; and

10. Pay all required fees.

10 B. A Multistate License granted pursuant to this Compact 11 may be effective for a definite period of time concurrent with the 12 renewal of the Home State license.

13 C. A Licensee practicing in a Member State is subject to all 14 scope of practice laws governing Massage Therapy Services in 15 that State.

16 D. The Practice of Massage Therapy under a Multistate 17 License granted pursuant to this Compact will subject the 18 Licensee to the jurisdiction of the Licensing Authority, the courts, 19 and the laws of the Member State in which the Massage Therapy 20 Services are provided.

21

9

22 23

23 24 25

### ARTICLE 5-AUTHORITY OF INTERSTATE MASSAGE COMPACT COMMISSION AND MEMBER STATE LICENSING AUTHORITIES

A. Nothing in this Compact, nor any Rule of the Commission,
shall be construed to limit, restrict, or in any way reduce the ability
of a Member State to enact and enforce laws, regulations, or other
rules related to the Practice of Massage Therapy in that State,
where those laws, regulations, or other rules are not inconsistent
with the provisions of this Compact.

B. Nothing in this Compact, nor any Rule of the Commission,
shall be construed to limit, restrict, or in any way reduce the ability
of a Member State to take Adverse Action against a Licensee's
Single-State License to practice Massage Therapy in that State.

C. Nothing in this Compact, nor any Rule of the Commission,
shall be construed to limit, restrict, or in any way reduce the ability
of a Remote State to take Adverse Action against a Licensee's
Authorization to Practice in that State.

40 D. Nothing in this Compact, nor any Rule of the 41 Commission, shall be construed to limit, restrict, or in any way 42 reduce the ability of a Licensee's Home State to take Adverse 43 Action against a Licensee's Multistate License based upon 44 information provided by a Remote State.





Insofar as practical, a Member State's Licensing Authority 1 **E**. 2 shall cooperate with the Commission and with each entity exercising independent regulatory authority over the Practice of 3 4 Massage Therapy according to the provisions of this Compact. 5

### **ARTICLE 6-ADVERSE ACTIONS**

A Licensee's Home State shall have exclusive power to 8 **A**. 9 impose an Adverse Action against a Licensee's Multistate License 10 issued by the Home State.

11 **B.** A Home State may take Adverse Action on a Multistate License based on the Investigative Information, 12 Current 13 Significant Investigative Information, or Adverse Action of a 14 Remote State.

C. A Home State shall retain authority to complete any 15 pending investigations of a Licensee practicing under a Multistate 16 17 License who changes their Home State during the course of such an investigation. The Licensing Authority shall also be empowered 18 to report the results of such an investigation to the Commission 19 20 through the Data System as described herein.

D. Any Member State may investigate actual or alleged 21 22 violations of the scope of practice laws in any other Member State 23 for a massage therapist who holds a Multistate License. 24

A Remote State shall have the authority to: **E**.

25 Take Adverse Actions against a Licensee's Authorization 1. 26 to Practice.

27 2. Issue cease and desist orders or impose an Encumbrance 28 on a Licensee's Authorization to Practice in that State.

29 3. Issue subpoenas for both hearings and investigations that require the attendance and testimony of witnesses, as well as the 30 production of evidence. Subpoenas issued by a Licensing 31 32 Authority in a Member State for the attendance and testimony of witnesses or the production of evidence from another Member 33 State shall be enforced in the latter State by any court of 34 competent jurisdiction, according to the practice and procedure of 35 that court applicable to subpoen issued in proceedings before it. 36 The issuing Licensing Authority shall pay any witness fees, travel 37 expenses, mileage, and other fees required by the service statutes 38 39 of the State in which the witnesses or evidence are located.

4. If otherwise permitted by State law, recover from the 40 affected Licensee the costs of investigations and disposition of 41 42 cases resulting from any Adverse Action taken against that 43 Licensee.





5. Take Adverse Action against the Licensee's Authorization 1 2 to Practice in that State based on the factual findings of another 3 Member State.

F. If an Adverse Action is taken by the Home State against a 4 5 Licensee's Multistate License or Single-State License to practice in the Home State. the Licensee's Authorization to Practice in all 6 7 other Member States shall be deactivated until all Encumbrances 8 have been removed from such license. All Home State disciplinary orders that impose an Adverse Action against a Licensee shall 9 10 include a statement that the Massage Therapist's Authorization to 11 Practice is deactivated in all Member States during the pendency 12 of the order.

13 **G**. If Adverse Action is taken by a Remote State against a 14 Licensee's Authorization to Practice, that Adverse Action applies to all Authorizations to Practice in all Remote States. A Licensee 15 whose Authorization to Practice in a Remote State is removed for 16 17 a specified period of time is not eligible to apply for a new Multistate License in any other State until the specific time for 18 19 removal of the Authorization to Practice has passed and all 20 encumbrance requirements are satisfied.

21 Nothing in this Compact shall override a Member State's *H*. 22 authority to accept a Licensee's participation in an Alternative 23 **Program** in lieu of Adverse Action. A Licensee's Multistate 24 License shall be suspended for the duration of the Licensee's 25 participation in any Alternative Program. 26

I. Joint Investigations

27 1. In addition to the authority granted to a Member State by 28 its respective scope of practice laws or other applicable State law, a 29 Member State may participate with other Member States in joint 30 investigations of Licensees.

31 2. Member States shall share any investigative, litigation, or 32 compliance materials in furtherance of any joint or individual investigation initiated under the Compact. 33 34

### **ARTICLE 7-ACTIVE MILITARY MEMBERS AND THEIR SPOUSES**

38 Active Military Members, or their spouses, shall designate a Home State where the individual has a current license to practice 39 Massage Therapy in good standing. The individual may retain 40 their Home State designation during any period of service when 41 42 that individual or their spouse is on active duty assignment.



35 36



1 2

### **ARTICLE 8-ESTABLISHMENT AND OPERATION OF** INTERSTATE MASSAGE COMPACT COMMISSION

3

12

The Compact Member States hereby create and establish a 4 **A**. 5 joint government agency whose membership consists of all Member States that have enacted the Compact known as the 6 Interstate Massage Compact Commission. The Commission is an 7 instrumentality of the Compact States acting jointly and not an 8 instrumentality of any one State. The Commission shall come into 9 existence on or after the effective date of the Compact as set forth 10 11 in Article 12.

**B**. Membership, Voting, and Meetings

13 1. Each Member State shall have and be limited to one (1) delegate selected by that Member State's State Licensing 14 15 Authority.

The delegate shall be the primary administrative officer of 16 2. 17 the State Licensing Authority or their designee.

18 3. The Commission shall by Rule or bylaw establish a term of office for delegates and may by Rule or bylaw establish term 19 20 limits.

21 4. The Commission may recommend removal or suspension 22 of any delegate from office.

23 5. A Member State's State Licensing Authority shall fill any 24 vacancy of its delegate occurring on the Commission within 60 25 days of the vacancy.

26 6. Each delegate shall be entitled to one vote on all matters 27 that are voted on by the Commission.

7. The Commission shall meet at least once during each 28 29 calendar year. Additional meetings may be held as set forth in the 30 bylaws. The Commission may meet by telecommunication, video conference or other similar electronic means. 31

32 C. The Commission shall have the following powers:

33 1. Establish the fiscal year of the Commission; 34

2. Establish code of conduct and conflict of interest policies;

35 *3*. Adopt Rules and bylaws;

Maintain its financial records in accordance with the 36 4. 37 bylaws:

38 5. Meet and take such actions as are consistent with the 39 provisions of this Compact, the Commission's Rules, and the 40 bylaws;

41 Initiate and conclude legal proceedings or actions in the **6**. 42 name of the Commission, provided that the standing of any State

43 Licensing Authority to sue or be sued under applicable law shall 44 *not be affected*;





1 7. Maintain and certify records and information provided to a 2 Member State as the authenticated business records of the 3 Commission, and designate an agent to do so on the Commission's 4 behalf;

8. Purchase and maintain insurance and bonds;

6 9. Borrow, accept, or contract for services of personnel, 7 including, but not limited to, employees of a Member State;

8 10. Conduct an annual financial review;

9 *11*. Hire employees, elect or appoint officers, fix compensation, define duties, grant such individuals appropriate 10 authority to carry out the purposes of the Compact, and establish 11 the Commission's personnel policies and programs relating to 12 13 conflicts of interest, qualifications of personnel, and other related personnel matters: 14

15

5

12. Assess and collect fees;

16 13. Accept any and all appropriate gifts, donations, grants of 17 money, other sources of revenue, equipment, supplies, materials, 18 and services, and receive, utilize, and dispose of the same; 19 provided that at all times the Commission shall avoid any 20 appearance of impropriety or conflict of interest;

21 14. Lease, purchase, retain, own, hold, improve, or use any 22 property, real, personal, or mixed, or any undivided interest 23 therein;

24 15. Sell, convey, mortgage, pledge, lease, exchange, abandon,
25 or otherwise dispose of any property real, personal, or mixed;

26 16. Establish a budget and make expenditures;

27 17. Borrow money;

28 18. Appoint committees, including standing committees, 29 composed of members, State regulators, State legislators or their 30 representatives, and consumer representatives, and such other 31 interested persons as may be designated in this Compact and the 32 bylaws;

19. Accept and transmit complaints from the public,
regulatory or law enforcement agencies, or the Commission, to the
relevant Member State(s) regarding potential misconduct of
Licensees;

37 20. Elect a Chair, Vice Chair, Secretary and Treasurer and 38 such other officers of the Commission as provided in the 39 Commission's bylaws;

40 21. Establish and elect an Executive Committee, including a 41 chair and a vice chair;

42 22. Adopt and provide to the Member States an annual 43 report;





6 D. The Executive Committee 7 1. The Executive Committee shall have the power to act on 8 behalf of the Commission according to the terms of this Compact. The powers, duties, and responsibilities of the Executive 9 10 Committee shall include: 11 a. Overseeing the day-to-day activities of the administration 12 of the Compact including compliance with the provisions of the 13 Compact, the Commission's Rules and bylaws, and other such 14 duties as deemed necessary: 15 b. Recommending to the Commission changes to the Rules or bylaws, changes to this Compact legislation, fees charged to 16 17 Compact Member States, fees charged to Licensees, and other 18 fees; 19 administration c. Ensuring Compact services are 20 appropriately provided, including by contract; 21 d. Preparing and recommending the budget; 22 e. Maintaining financial records on behalf of the 23 *Commission*; 24 f. Monitoring Compact compliance of Member States and 25 providing compliance reports to the Commission; 26 g. Establishing additional committees as necessary; 27 h. Exercise the powers and duties of the Commission 28 during the interim between Commission meetings, except for adopting or amending Rules, adopting or amending bylaws, and 29 exercising any other powers and duties expressly reserved to the 30 31 Commission by Rule or bylaw; and 32 i. Other duties as provided in the Rules or bylaws of the 33 Commission. 2. The Executive Committee shall be composed of seven 34 35 voting members and up to two ex-officio members as follows: a. The chair and vice chair of the Commission and any 36 37 other members of the Commission who serve on the Executive Committee shall be voting members of the Executive Committee. 38 b. Other than the chair, vice-chair, secretary and treasurer, 39 40 the Commission shall elect three voting members from the current membership of the Commission. 41 42 c. The Commission may elect ex-officio, nonvoting 43 members as necessary as follows: 44 *i.* One ex-officio member who is a representative of the 45 national association of State Massage Therapy regulatory boards. SB161 R3

- 22 -

materially different from the model Compact language such that the State would not qualify for participation in the Compact; and

appropriate to achieve the purposes of this Compact.

24. Perform such other functions as may be necessary or

Determine whether a State's adopted language is

*23*.

1 2

3

1 ii. One ex-officio member as specified in the 2 Commission's bylaws.

The Commission may remove any member of the Executive 3 3. *Committee as provided in the Commission's bylaws.* 4 5

4. The Executive Committee shall meet at least annually.

a. Executive Committee meetings shall be open to the 6 7 public, except that the Executive Committee may meet in a closed, 8 non-public session of a public meeting when dealing with any of the matters covered under subsection F.4. 9

10 b. The Executive Committee shall give five business days advance notice of its public meetings, posted on its website and as 11 12 determined to provide notice to persons with an interest in the 13 public matters the Executive Committee intends to address at those 14 *meetings*.

15 5. The Executive Committee may hold an emergency meeting 16 when acting for the Commission to:

17 a. Meet an imminent threat to public health, safety, or 18 welfare;

b. Prevent a loss of Commission or Participating State 19 20 funds; or 21

c. Protect public health and safety.

22 The Commission shall adopt and provide to the Member **E**. 23 States an annual report. 24

**F**. Meetings of the Commission

25 1. All meetings of the Commission that are not closed 26 pursuant to this subsection shall be open to the public. Notice of 27 public meetings shall be posted on the Commission's website at 28 least thirty (30) days prior to the public meeting.

29 2. Notwithstanding subsection F.1 of this Article, the Commission may convene an emergency public meeting by 30 providing at least twenty-four (24) hours prior notice on the 31 32 Commission's website, and any other means as provided in the Commission's Rules, for any of the reasons it may dispense with 33 notice of proposed rulemaking under Article 10.L. The 34 Commission's legal counsel shall certify that one of the reasons 35 justifying an emergency public meeting has been met. 36

37 3. Notice of all Commission meetings shall provide the time, date, and location of the meeting, and if the meeting is to be held 38 or accessible via telecommunication, video conference, or other 39 electronic means, the notice shall include the mechanism for 40 41 access to the meeting.

42 4. The Commission may convene in a closed, non-public 43 *meeting for the Commission to discuss:* 

44 a. Non-compliance of a Member State with its obligations 45 under the Compact;





-23 -

b. The employment, compensation, discipline or other 1 2 matters, practices or procedures related to specific employees or other matters related to the Commission's internal personnel 3 4 practices and procedures: 5 c. Current or threatened discipline of a Licensee by the 6 *Commission or by a Member State's Licensing Authority;* 7 d. Current, threatened, or reasonably anticipated litigation; 8 e. Negotiation of contracts for the purchase, lease, or sale 9 of goods, services, or real estate: 10 f. Accusing any person of a crime or formally censuring 11 any person; 12 g. Trade secrets or commercial or financial information 13 that is privileged or confidential; h. Information of a personal nature where disclosure would 14 15 constitute a clearly unwarranted invasion of personal privacy; *i.* Investigative records compiled for law enforcement 16 17 purposes; 18 j. Information related to any investigative reports prepared by or on behalf of or for use of the Commission or other 19 20 committee charged with responsibility of investigation or 21 determination of compliance issues pursuant to the Compact; 22 k. Legal advice: 23 *l.* Matters specifically exempted from disclosure to the 24 public by federal or Member State law: or 25 m. Other matters as promulgated by the Commission by 26 Rule. 27 5. If a meeting, or portion of a meeting, is closed, the 28 presiding officer shall state that the meeting will be closed and 29 reference each relevant exempting provision, and such reference 30 shall be recorded in the minutes. 6. The Commission shall keep minutes that fully and clearly 31 describe all matters discussed in a meeting and shall provide a full 32 and accurate summary of actions taken, and the reasons 33 therefore, including a description of the views expressed. All 34 documents considered in connection with an action shall be 35 identified in such minutes. All minutes and documents of a closed 36 37 meeting shall remain under seal, subject to release only by a majority vote of the Commission or order of a court of competent 38 39 *jurisdiction*. 40 G. Financing of the Commission The Commission shall pay, or provide for the payment of, 41 1. 42 the reasonable expenses of its establishment, organization, and

43 ongoing activities.





The Commission may accept any and all appropriate 1 2. 2 sources of revenue, donations, and grants of money, equipment, 3 supplies, materials, and services.

3. The Commission may levy on and collect an annual 4 5 assessment from each Member State and impose fees on Licensees 6 of Member States to whom it grants a Multistate License to cover 7 the cost of the operations and activities of the Commission and its 8 staff, which must be in a total amount sufficient to cover its 9 annual budget as approved each year for which revenue is not provided by other sources. The aggregate annual assessment 10 11 amount for Member States shall be allocated based upon a 12 formula that the Commission shall promulgate by Rule.

13 4. The Commission shall not incur obligations of any kind 14 prior to securing the funds adequate to meet the same; nor shall 15 the Commission pledge the credit of any Member States, except by 16 and with the authority of the Member State.

17 The Commission shall keep accurate accounts of all 5. receipts and disbursements. The receipts and disbursements of the 18 Commission shall be subject to the financial review and 19 20 accounting procedures established under its bylaws. All receipts 21 and disbursements of funds handled by the Commission shall be subject to an annual financial review by a certified or licensed 22 23 public accountant, and the report of the financial review shall be 24 included in and become part of the annual report of the 25 Commission. 26

Qualified Immunity, Defense, and Indemnification **H**.

27 1. The members, officers, executive director, employees and 28 representatives of the Commission shall be immune from suit and 29 liability, both personally and in their official capacity, for any claim for damage to or loss of property or personal injury or other 30 civil liability caused by or arising out of any actual or alleged act, 31 32 error, or omission that occurred, or that the person against whom 33 the claim is made had a reasonable basis for believing occurred 34 within the scope of Commission employment, duties or 35 responsibilities; provided that nothing in this paragraph shall be construed to protect any such person from suit or liability for any 36 37 damage, loss, injury, or liability caused by the intentional or willful or wanton misconduct of that person. The procurement of 38 insurance of any type by the Commission shall not in any way 39 40 compromise or limit the immunity granted hereunder.

The Commission shall defend any member, officer, 41 2. 42 director, employee, and representative executive of the 43 Commission in any civil action seeking to impose liability arising 44 out of any actual or alleged act, error, or omission that occurred 45 within the scope of Commission employment, duties, or





responsibilities, or as determined by the Commission that the 1 person against whom the claim is made had a reasonable basis for 2 believing occurred within the scope of Commission employment, 3 duties, or responsibilities; provided that nothing herein shall be 4 5 construed to prohibit that person from retaining their own counsel at their own expense; and provided further, that the actual or 6 7 alleged act, error, or omission did not result from that person's 8 intentional or willful or wanton misconduct.

The Commission shall indemnify and hold harmless any 9 *3*. 10 member, officer, executive director, employee, and representative 11 of the Commission for the amount of any settlement or judgment 12 obtained against that person arising out of any actual or alleged 13 act, error, or omission that occurred within the scope of Commission employment, duties, or responsibilities, or that such 14 person had a reasonable basis for believing occurred within the 15 scope of Commission employment, duties, or responsibilities, 16 17 provided that the actual or alleged act, error, or omission did not result from the intentional or willful or wanton misconduct of that 18 19 person.

4. Nothing herein shall be construed as a limitation on the liability of any Licensee for professional malpractice or misconduct, which shall be governed solely by any other applicable State laws.

5. Nothing in this Compact shall be interpreted to waive or
otherwise abrogate a Member State's State action immunity or
State action affirmative defense with respect to antitrust claims
under the Sherman Act, Clayton Act, or any other State or federal
antitrust or anticompetitive law or regulation.

29 6. Nothing in this Compact shall be construed to be a waiver 30 of sovereign immunity by the Member States or by the 31 Commission.

#### **ARTICLE 9-DATA SYSTEM**

A. The Commission shall provide for the development,
 maintenance, operation, and utilization of a coordinated database
 and reporting system.

38 B. The Commission shall assign each applicant for a 39 Multistate License a unique identifier, as determined by the Rules 40 of the Commission.

41 C. Notwithstanding any other provision of State law to the 42 contrary, a Member State shall submit a uniform data set to the 43 Data System on all individuals to whom this Compact is applicable 44 as required by the Rules of the Commission, including:

45 1. Identifying information;



32 33



1 2. Licensure data;

2 3. Adverse Actions against a license and information related 3 thereto;

4 4. Non-confidential information related to Alternative 5 Program participation, the beginning and ending dates of such 6 participation, and other information related to such participation;

7 5. Any denial of application for licensure, and the reason(s)
8 for such denial (excluding the reporting of any criminal history
9 record information where prohibited by law);

10

6. The existence of Investigative Information;

7. The existence presence of Current Significant Investigative
 Information; and

8. Other information that may facilitate the administration of
this Compact or the protection of the public, as determined by the
Rules of the Commission.

16 D. The records and information provided to a Member State 17 pursuant to this Compact or through the Data System, when 18 certified by the Commission or an agent thereof, shall constitute 19 the authenticated business records of the Commission, and shall 20 be entitled to any associated hearsay exception in any relevant 21 judicial, quasi-judicial or administrative proceedings in a Member 22 State.

23 E. The existence of Current Significant Investigative 24 Information and the existence of Investigative Information 25 pertaining to a Licensee in any Member State will only be 26 available to other Member States.

F. It is the responsibility of the Member States to report any
Adverse Action against a Licensee who holds a Multistate License
and to monitor the database to determine whether Adverse Action
has been taken against such a Licensee or License applicant.
Adverse Action information pertaining to a Licensee or License
applicant in any Member State will be available to any other
Member State.

34 G. Member States contributing information to the Data 35 System may designate information that may not be shared with the 36 public without the express permission of the contributing State.

H. Any information submitted to the Data System that is
subsequently expunged pursuant to federal law or the laws of the
Member State contributing the information shall be removed from
the Data System.

#### 41 42

## 43

### **ARTICLE 10-RULEMAKING**

44 A. The Commission shall promulgate reasonable Rules in 45 order to effectively and efficiently implement and administer the



1 purposes and provisions of the Compact. A Rule shall be invalid 2 and have no force or effect only if a court of competent 3 jurisdiction holds that the Rule is invalid because the Commission 4 exercised its rulemaking authority in a manner that is beyond the 5 scope and purposes of the Compact, or the powers granted 6 hereunder, or based upon another applicable standard of review.

7 B. The Rules of the Commission shall have the force of law 8 in each Member State, provided however that where the Rules of 9 the Commission conflict with the laws of the Member State that 10 establish the Member State's scope of practice as held by a court 11 of competent jurisdiction, the Rules of the Commission shall be 12 ineffective in that State to the extent of the conflict.

13 C. The Commission shall exercise its Rulemaking powers 14 pursuant to the criteria set forth in this article and the Rules 15 adopted thereunder. Rules shall become binding as of the date 16 specified by the Commission for each Rule.

17 D. If a majority of the legislatures of the Member States 18 rejects a Rule or portion of a Rule, by enactment of a statute or 19 resolution in the same manner used to adopt the Compact within 20 four (4) years of the date of adoption of the Rule, then such Rule 21 shall have no further force and effect in any Member State or to 22 any State applying to participate in the Compact.

23 E. Rules shall be adopted at a regular or special meeting of 24 the Commission.

F. Prior to adoption of a proposed Rule, the Commission
shall hold a public hearing and allow persons to provide oral and
written comments, data, facts, opinions, and arguments.

G. Prior to adoption of a proposed Rule by the Commission,
and at least thirty (30) days in advance of the meeting at which the
Commission will hold a public hearing on the proposed Rule, the
Commission shall provide a Notice of Proposed Rulemaking:

32 1. On the website of the Commission or other publicly 33 accessible platform;

34 2. To persons who have requested notice of the Commission's
 35 notices of proposed rulemaking, and

36 3. In such other way(s) as the Commission may by Rule 37 specify.

38 H. The Notice of Proposed Rulemaking shall include:

*1. The time, date, and location of the public hearing at which the Commission will hear public comments on the proposed Rule and, if different, the time, date, and location of the meeting where the Commission will consider and vote on the proposed Rule;*

43 2. If the hearing is held via telecommunication, video 44 conference, or other electronic means, the Commission shall





include the mechanism for access to the hearing in the Notice of
 Proposed Rulemaking;

3. The text of the proposed Rule and the reason therefor;

4 4. A request for comments on the proposed Rule from any 5 interested person; and

6 5. The manner in which interested persons may submit 7 written comments.

8 I. All hearings will be recorded. A copy of the recording and 9 all written comments and documents received by the Commission 10 in response to the proposed Rule shall be available to the public.

11 J. Nothing in this article shall be construed as requiring a 12 separate hearing on each Rule. Rules may be grouped for the 13 convenience of the Commission at hearings required by this 14 article.

15 K. The Commission shall, by majority vote of all 16 Commissioners, take final action on the proposed Rule based on 17 the Rulemaking record.

18 1. The Commission may adopt changes to the proposed Rule 19 provided the changes do not enlarge the original purpose of the 20 proposed Rule.

21 2. The Commission shall provide an explanation of the 22 reasons for substantive changes made to the proposed Rule as well 23 as reasons for substantive changes not made that were 24 recommended by commenters.

25 3. The Commission shall determine a reasonable effective 26 date for the Rule. Except for an emergency as provided in 27 subsection L, the effective date of the Rule shall be no sooner than 28 thirty (30) days after the Commission issuing the notice that it 29 adopted or amended the Rule.

30 L. Upon determination that an emergency exists, the Commission may consider and adopt an emergency Rule with 24 31 32 hours' notice, provided that the usual Rulemaking procedures provided in the Compact and in this article shall be retroactively 33 applied to the Rule as soon as reasonably possible, in no event 34 later than ninety (90) days after the effective date of the Rule. For 35 the purposes of this provision, an emergency Rule is one that must 36 37 *be adopted immediately to:* 

38 1. Meet an imminent threat to public health, safety, or 39 welfare;

40 2. Prevent a loss of Commission or Member State funds;

41 3. Meet a deadline for the promulgation of a Rule that is 42 established by federal law or rule; or

43 **4. Protect public health and safety.** 

44 M. The Commission or an authorized committee of the 45 Commission may direct revisions to a previously adopted Rule for





1 purposes of correcting typographical errors, errors in format, 2 errors in consistency, or grammatical errors. Public notice of any revisions shall be posted on the website of the Commission. The 3 revision shall be subject to challenge by any person for a period of 4 5 thirty (30) days after posting. The revision may be challenged only on grounds that the revision results in a material change to a 6 7 Rule. A challenge shall be made in writing and delivered to the 8 Commission prior to the end of the notice period. If no challenge is made, the revision will take effect without further action. If the 9 10 revision is challenged, the revision may not take effect without the 11 approval of the Commission.

N. No Member State's rulemaking requirements shall apply
 under this Compact.

ARTICLE 11-OVERSIGHT, DISPUTE RESOLUTION, AND ENFORCEMENT

A. Oversight

19 1. The executive and judicial branches of State government 20 in each Member State shall enforce this Compact and take all 21 actions necessary and appropriate to implement the Compact.

22 Venue is proper and judicial proceedings by or against the 2. 23 Commission shall be brought solely and exclusively in a court of 24 competent jurisdiction where the principal office of the Commission is located. The Commission may waive venue and 25 26 jurisdictional defenses to the extent it adopts or consents to 27 participate in alternative dispute resolution proceedings. Nothing 28 herein shall affect or limit the selection or propriety of venue in 29 any action against a Licensee for professional malpractice, 30 misconduct or any such similar matter.

31 3. The Commission shall be entitled to receive service of 32 process in any proceeding regarding the enforcement or 33 interpretation of the Compact and shall have standing to intervene 34 in such a proceeding for all purposes. Failure to provide the 35 Commission service of process shall render a judgment or order 36 void as to the Commission, this Compact, or promulgated Rules.

37

15

16 17 18

**B.** Default, Technical Assistance, and Termination

38 1. If the Commission determines that a Member State has defaulted in the performance of its obligations or responsibilities 39 40 under this Compact or the promulgated Rules, the Commission shall provide written notice to the defaulting State. The notice of 41 42 default shall describe the default, the proposed means of curing the default, and any other action that the Commission may take, 43 44 and shall offer training and specific technical assistance 45 regarding the default.





The Commission shall provide a copy of the notice of 1 2. 2 default to the other Member States.

3 C. If a State in default fails to cure the default, the defaulting State may be terminated from the Compact upon an affirmative 4 5 vote of a majority of the delegates of the Member States, and all rights, privileges and benefits conferred on that State by this 6 7 Compact may be terminated on the effective date of termination. A cure of the default does not relieve the offending State of 8 9 obligations or liabilities incurred during the period of default.

10 Termination of membership in the Compact shall be **D**. imposed only after all other means of securing compliance have 11 12 been exhausted. Notice of intent to suspend or terminate shall be 13 given by the Commission to the governor, the majority and minority leaders of the defaulting State's legislature, the 14 15 defaulting State's State Licensing Authority and each of the 16 Member States' State Licensing Authority.

17 **E**. A State that has been terminated is responsible for all assessments, obligations, and liabilities incurred through the 18 effective date of termination, including obligations that extend 19 20 beyond the effective date of termination.

Upon the termination of a State's membership from this 21 **F**. 22 Compact, that State shall immediately provide notice to all 23 Licensees who hold a Multistate License within that State of such 24 termination. The terminated State shall continue to recognize all 25 licenses granted pursuant to this Compact for a minimum of one 26 hundred eighty (180) days after the date of said notice of 27 termination.

28 G. The Commission shall not bear any costs related to a State 29 that is found to be in default or that has been terminated from the 30 Compact, unless agreed upon in writing between the Commission 31 and the defaulting State.

32 The defaulting State may appeal the action of the **H**. Commission by petitioning the U.S. District Court for the District 33 of Columbia or the federal district where the Commission has its 34 35 principal offices. The prevailing party shall be awarded all costs of 36 such litigation, including reasonable attorney's fees. 37

I. Dispute Resolution

38 1. Upon request by a Member State, the Commission shall attempt to resolve disputes related to the Compact that arise 39 40 among Member States and between Member and non-Member States. 41

42 2. The Commission shall promulgate a Rule providing for 43 both mediation and binding dispute resolution for disputes as 44 appropriate.

45 J. Enforcement





The Commission, in the reasonable exercise of its 1 1. 2 discretion, shall enforce the provisions of this Compact and the 3 Commission's Rules.

By majority vote as provided by Commission Rule, the 4 2. 5 Commission may initiate legal action against a Member State in default in the United States District Court for the District of 6 7 Columbia or the federal district where the Commission has its 8 principal offices to enforce compliance with the provisions of the Compact and its promulgated Rules. The relief sought may 9 include both injunctive relief and damages. In the event judicial 10 11 enforcement is necessary, the prevailing party shall be awarded all 12 costs of such litigation, including reasonable attorney's fees. The 13 remedies herein shall not be the exclusive remedies of the Commission. The Commission may pursue any other remedies 14 available under federal or the defaulting Member State's law. 15

3. A Member State may initiate legal action against the 16 17 Commission in the U.S. District Court for the District of Columbia or the federal district where the Commission has its principal 18 offices to enforce compliance with the provisions of the Compact 19 20 and its promulgated Rules. The relief sought may include both 21 injunctive relief and damages. In the event judicial enforcement is 22 necessary, the prevailing party shall be awarded all costs of such 23 litigation, including reasonable attorney's fees.

24 No individual or entity other than a Member State may 4. 25 enforce this Compact against the Commission. 26

#### **ARTICLE 12-EFFECTIVE DATE, WITHDRAWAL,** AND AMENDMENT

30 *A*. The Compact shall come into effect on the date on which the Compact statute is enacted into law in the seventh Member 31 32 State.

33 1. On or after the effective date of the Compact, the Commission shall convene and review the enactment of each of 34 the Charter Member States to determine if the statute enacted by 35 each such Charter Member State is materially different than the 36 37 model Compact statute.

38 a. A Charter Member State whose enactment is found to be materially different from the model Compact statute shall be 39 40 entitled to the default process set forth in Article 11.

b. If any Member State is later found to be in default, or is 41 42 terminated or withdraws from the Compact, the Commission shall 43 remain in existence and the Compact shall remain in effect even if 44

the number of Member States should be less than seven (7).



27

28



1 2. Member States enacting the Compact subsequent to the 2 Charter Member States shall be subject to the process set forth in 3 Article 8.C.23 to determine if their enactments are materially 4 different from the model Compact statute and whether they qualify 5 for participation in the Compact.

6 3. All actions taken for the benefit of the Commission or in 7 furtherance of the purposes of the administration of the Compact 8 prior to the effective date of the Compact or the Commission 9 coming into existence shall be considered to be actions of the 10 Commission unless specifically repudiated by the Commission.

4. Any State that joins the Compact shall be subject to the Commission's Rules and bylaws as they exist on the date on which the Compact becomes law in that State. Any Rule that has been previously adopted by the Commission shall have the full force and effect of law on the day the Compact becomes law in that State.

17 B. Any Member State may withdraw from this Compact by 18 enacting a statute repealing that State's enactment of the 19 Compact.

20 1. A Member State's withdrawal shall not take effect until 21 one hundred eighty (180) days after enactment of the repealing 22 statute.

23 2. Withdrawal shall not affect the continuing requirement of 24 the withdrawing State's Licensing Authority to comply with the 25 investigative and Adverse Action reporting requirements of this 26 Compact prior to the effective date of withdrawal.

3. Upon the enactment of a statute withdrawing from this
Compact, a State shall immediately provide notice of such
withdrawal to all Licensees within that State. Notwithstanding any
subsequent statutory enactment to the contrary, such withdrawing
State shall continue to recognize all licenses granted pursuant to
this Compact for a minimum of 180 days after the date of such
notice of withdrawal.

C. Nothing contained in this Compact shall be construed to
invalidate or prevent any licensure agreement or other cooperative
arrangement between a Member State and a non-Member State
that does not conflict with the provisions of this Compact.

38 D. This Compact may be amended by the Member States. No 39 amendment to this Compact shall become effective and binding 40 upon any Member State until it is enacted into the laws of all 41 Member States.





1 2

### **ARTICLE 13. CONSTRUCTION AND SEVERABILITY**

3 This Compact and the Commission's rulemaking authority Α. shall be liberally construed so as to effectuate the purposes, and 4 5 the implementation and administration of the Compact. Provisions 6 of the Compact expressly authorizing or requiring the 7 promulgation of Rules shall not be construed to limit the 8 *Commission's rulemaking authority solely for those purposes.* 

The provisions of this Compact shall be severable and if 9 **B**. any phrase, clause, sentence or provision of this Compact is held 10 by a court of competent jurisdiction to be contrary to the 11 constitution of any Member State, a State seeking participation in 12 13 the Compact, or of the United States, or the applicability thereof to any government, agency, person or circumstance is held to be 14 unconstitutional by a court of competent jurisdiction, the validity 15 of the remainder of this Compact and the applicability thereof to 16 any other government, agency, person or circumstance shall not 17 18 be affected thereby.

19 Notwithstanding subsection B of this article. the С. 20 Commission may deny a State's participation in the Compact or, 21 in accordance with the requirements of Article 11.B, terminate a 22 Member State's participation in the Compact, if it determines that a constitutional requirement of a Member State is a material 23 24 departure from the Compact. Otherwise, if this Compact shall be 25 held to be contrary to the constitution of any Member State, the Compact shall remain in full force and effect as to the remaining 26 27 Member States and in full force and effect as to the Member State 28 affected as to all severable matters.

- 29
- 30 31 32

### **ARTICLE 14. CONSISTENT EFFECT AND CONFLICT WITH OTHER STATE LAWS**

33 Nothing herein shall prevent or inhibit the enforcement of any 34 other law of a Member State that is not inconsistent with the 35 Compact.

Any laws, statutes, regulations, or other legal requirements in a 36 37 Member State in conflict with the Compact are superseded to the 38 extent of the conflict.

- 39 All permissible agreements between the Commission and the Member States are binding in accordance with their terms. 40
- **Sec. 8.** NRS 640C.180 is hereby amended to read as follows: 41

42 640C.180 1. At the first meeting of each fiscal year, the members of the Board shall elect a Chair, Vice Chair and Secretary-43 44 Treasurer from among the members.





1 2. The Board shall meet at least quarterly and may meet at 2 other times at the call of the Chair or upon the written request of a 3 majority of the members of the Board.

4 3. The Board shall alternate the location of its meetings 5 between the southern district of Nevada and the northern district of 6 Nevada. For the purposes of this subsection:

7 (a) The southern district of Nevada consists of all that portion of
8 the State lying within the boundaries of the counties of Clark,
9 Esmeralda, Lincoln and Nye.

(b) The northern district of Nevada consists of all that portion of
the State lying within the boundaries of Carson City and the
counties of Churchill, Douglas, Elko, Eureka, Humboldt, Lander,
Lyon, Mineral, Pershing, Storey, Washoe and White Pine.

4. A meeting of the Board may be conducted telephonically or
by videoconferencing. A meeting conducted telephonically or by
videoconferencing must meet the requirements of chapter 241 of
NRS and any other applicable provisions of law.

18 5. [Four] *Five* members of the Board constitute a quorum for 19 the purposes of transacting the business of the Board, including, 20 without limitation, issuing, renewing, suspending, revoking or 21 reinstating a license issued pursuant to this chapter.

**Sec. 9.** NRS 683A.178 is hereby amended to read as follows:

683A.178 1. A pharmacy benefit manager has an obligation of good faith and fair dealing toward a third party or pharmacy when performing duties pursuant to a contract to which the pharmacy benefit manager is a party. Any provision of a contract that waives or limits that obligation is against public policy, void and unenforceable.

29 2. A pharmacy benefit manager shall notify a third party with 30 which it has entered into a contract in writing of any activity, policy 31 or practice of the pharmacy benefit manager that presents a conflict 32 of interest that interferes with the obligations imposed by 33 subsection 1.

34 3. A pharmacy benefit manager that manages prescription 35 drug benefits for an insurer licensed pursuant to this title shall 36 comply with the provisions of this title which are applicable to the 37 insurer when managing such benefits for the insurer.

38 Sec. 10. Chapter 687B of NRS is hereby amended by adding 39 thereto a new section to read as follows:

40 1. A health carrier which offers or issues a network plan:

41 (a) Must demonstrate the capacity to adequately deliver family 42 planning services provided by pharmacists or pharmacies to 43 covered persons in accordance with the regulations adopted 44 pursuant to subsection 2.





1 (b) Shall make available to each covered person in this State a 2 notice that meets the requirements prescribed by the regulations 3 adopted pursuant to subsection 2 of each pharmacist or pharmacy 4 that has entered into a provider network contract with the carrier 5 to provide family planning services to covered persons who 6 participate in the relevant network plan.

7 2. The Commissioner shall adopt regulations to carry out the 8 provisions of this section, including, without limitation, 9 regulations prescribing requirements for:

10 (a) A health carrier to demonstrate compliance with paragraph 11 (a) of subsection 1. Those regulations must not allow a health 12 carrier to demonstrate the capacity to adequately deliver family 13 planning services to covered persons by demonstrating that the 14 health carrier has entered into a network contract with one or 15 more pharmacies for the sole purpose of dispensing prescription 16 drugs to covered persons.

(b) The form and contents of the notice required by paragraph
(b) of subsection 1.

NRS 687B.225 is hereby amended to read as follows: 19 Sec. 11. 20 687B.225 1. Except otherwise provided NRS as in 689A.0412. 689A.0418. 21 689A.0405. 689A.0413. 689A.044. 22 689B.0315, 689A.0445, 689B.031, 689B.0313, 689B.0317. 23 689B.0378, 689C.1675. 689C.1676, 695A.1856. 689B.0374. 24 695B.1912. 695B.1913. 695A.1865. 695B.1914. 695B.1919. 695C.1713, 25 695B.1925, 695B.1942, 695C.1696, 695C.1735. 26 695C.1737. 695C.1745. 695C.1751, 695G.170. 695G.171. 695G.1714, 695G.1715 and 695G.177, any contract for group, 27 28 blanket or individual health insurance or any contract by a nonprofit 29 hospital, medical or dental service corporation or organization for 30 dental care which provides for payment of a certain part of medical 31 or dental care may require the insured or member to obtain prior 32

authorization for that care from the insurer or organization. The
 insurer or organization shall:
 (a) File its procedure for obtaining approval of care pursuant to

(a) File its procedure for obtaining approval of care pursuant tothis section for approval by the Commissioner; and

(b) Respond to any request for approval by the insured or
member pursuant to this section within 20 days after it receives the
request.

39 2. The procedure for prior authorization may not discriminate40 among persons licensed to provide the covered care.

41 Sec. 12. NRS 687B.600 is hereby amended to read as follows:

42 687B.600 As used in NRS 687B.600 to 687B.850, inclusive, 43 *and section 11 of this act,* unless the context otherwise requires, the 44 words and terms defined in NRS 687B.602 to 687B.665, inclusive, 45 have the meanings ascribed to them in those sections.





1 Sec. 13. NRS 687B.670 is hereby amended to read as follows: 2 687B.670 If a health carrier offers or issues a network plan, the 3 health carrier shall, with regard to that network plan: 4 Comply with all applicable requirements set forth in NRS 1. 5 687B.600 to 687B.850, inclusive [;], and section 11 of this act; 6 2. As applicable, ensure that each contract entered into for the purposes of the network plan between a participating provider of 7 8 health care and the health carrier complies with the requirements set 9 forth in NRS 687B.600 to 687B.850, inclusive [;], and section 11 10 of this act: and 11 3. As applicable, ensure that the network plan complies with 12 the requirements set forth in NRS 687B.600 to 687B.850, inclusive 13 [.], and section 11 of this act. 14 Sec. 14. NRS 689A.0418 is hereby amended to read as 15 follows: 16 689A.0418 1. Except as otherwise provided in subsection [7,] 17 8, an insurer that offers or issues a policy of health insurance shall 18 include in the policy coverage for: 19 (a) Up to a 12-month supply, per prescription, of any type of 20 drug for contraception or its therapeutic equivalent which is: 21 (1) Lawfully prescribed or ordered; 22 (2) Approved by the Food and Drug Administration; 23 (3) Listed in subsection [10;] 11; and 24 (4) Dispensed in accordance with NRS 639.28075: 25 (b) Any type of device for contraception which is: (1) Lawfully prescribed or ordered; 26 27 (2) Approved by the Food and Drug Administration; and 28 (3) Listed in subsection [10;] 11; 29 (c) Self-administered hormonal contraceptives dispensed by a 30 pharmacist pursuant to NRS 639.28078; 31 (d) Insertion of a device for contraception or removal of such a 32 device if the device was inserted while the insured was covered by 33 the same policy of health insurance; (e) Education and counseling relating to the initiation of the use 34 35 of contraception and any necessary follow-up after initiating such 36 use: 37 (f) Management of side effects relating to contraception; and 38 (g) Voluntary sterilization for women. 39 2. An insurer shall provide coverage for any services listed in 40 subsection 1 which are within the authorized scope of practice of a 41 pharmacist when such services are provided by a pharmacist who 42 is employed by or serves as an independent contractor of an in-43 network pharmacy and in accordance with the applicable provider 44 network contract. Such coverage must be provided to the same 45 extent as if the services were provided by another provider of





– 38 –

health care, as applicable to the services being provided. The terms
 of the policy must not limit:

3 (a) Coverage for services listed in subsection 1 and provided by 4 such a pharmacist to a number of occasions less than the coverage 5 for such services when provided by another provider of health 6 care.

7 (b) Reimbursement for services listed in subsection 1 and 8 provided by such a pharmacist to an amount less than the amount 9 reimbursed for similar services provided by a physician, physician 10 assistant or advanced practice registered nurse.

**3.** An insurer must ensure that the benefits required by subsection 1 are made available to an insured through a provider of health care who participates in the network plan of the insurer.

14 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 15 is not available or a provider of health care deems a covered 16 therapeutic equivalent to be medically inappropriate, an alternate 17 therapeutic equivalent prescribed by a provider of health care must 18 be covered by the insurer.

19 [4.] 5. Except as otherwise provided in subsections [8.] 9, 10 20 and [11.] 12, an insurer that offers or issues a policy of health 21 insurance shall not:

(a) Require an insured to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition for coverage to obtain any benefit included in the
policy pursuant to subsection 1;

(b) Refuse to issue a policy of health insurance or cancel a
policy of health insurance solely because the person applying for or
covered by the policy uses or may use any such benefit;

(c) Offer or pay any type of material inducement or financial
 incentive to an insured to discourage the insured from obtaining any
 such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an insured, including, without limitation, reducing the
reimbursement of the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
financial incentive to a provider of health care to deny, reduce,
withhold, limit or delay access to any such benefit to an insured; or

(f) Impose any other restrictions or delays on the access of aninsured any such benefit.

40 [5.] 6. Coverage pursuant to this section for the covered 41 dependent of an insured must be the same as for the insured.

42 [6.] 7. Except as otherwise provided in subsection [7,] 8, a 43 policy subject to the provisions of this chapter that is delivered, 44 issued for delivery or renewed on or after January 1, [2022,] 2024, 45 has the legal effect of including the coverage required by





1 [subsection 1,] *this section*, and any provision of the policy or the 2 renewal which is in conflict with this section is void.

3 7. 8. An insurer that offers or issues a policy of health 4 insurance and which is affiliated with a religious organization is not 5 required to provide the coverage required by subsection 1 if the 6 insurer objects on religious grounds. Such an insurer shall, before 7 the issuance of a policy of health insurance and before the renewal 8 of such a policy, provide to the prospective insured written notice of 9 the coverage that the insurer refuses to provide pursuant to this 10 subsection.

11 [8.] 9. An insurer may require an insured to pay a higher 12 deductible, copayment or coinsurance for a drug for contraception if 13 the insured refuses to accept a therapeutic equivalent of the drug.

14 **9. 10.** For each of the 18 methods of contraception listed in 15 subsection [10] 11 that have been approved by the Food and Drug 16 Administration, a policy of health insurance must include at least 17 one drug or device for contraception within each method for which 18 no deductible, copayment or coinsurance may be charged to the 19 insured, but the insurer may charge a deductible, copayment or 20 coinsurance for any other drug or device that provides the same 21 method of contraception. If the insurer charges a copayment or 22 coinsurance for a drug for contraception, the insurer may only 23 require an insured to pay the copayment or coinsurance:

### 24 (a) Once for the entire amount of the drug dispensed for the 25 plan year; or

- 26 (b) Once for each 1-month supply of the drug dispensed.
- 27 [10.] 11. The following 18 methods of contraception must be 28 covered pursuant to this section:
- 29 (a) Voluntary sterilization for women;
- 30 (b) Surgical sterilization implants for women;
- 31 (c) Implantable rods;
- 32 (d) Copper-based intrauterine devices;
- 33 (e) Progesterone-based intrauterine devices;
- 34 (f) Injections;
- 35 (g) Combined estrogen- and progestin-based drugs;
- 36 (h) Progestin-based drugs;
- 37 (i) Extended- or continuous-regimen drugs;
- 38 (j) Estrogen- and progestin-based patches;
- 39 (k) Vaginal contraceptive rings;
- 40 (1) Diaphragms with spermicide;
- 41 (m) Sponges with spermicide;
- 42 (n) Cervical caps with spermicide;
- 43 (o) Female condoms;
- 44 (p) Spermicide;





1 (q) Combined estrogen- and progestin-based drugs for 2 emergency contraception or progestin-based drugs for emergency 3 contraception; and

4

(r) Úlipristal acetate for emergency contraception.

5 [11.] 12. Except as otherwise provided in this section and 6 federal law, an insurer may use medical management techniques, 7 including, without limitation, any available clinical evidence, to 8 determine the frequency of or treatment relating to any benefit 9 required by this section or the type of provider of health care to use 10 for such treatment.

11

[12.] 13. An insurer shall not [use] :

(a) Use medical management techniques to require an insured to
 use a method of contraception other than the method prescribed or
 ordered by a provider of health care [.]; or

15 (b) Require an insured to obtain prior authorization for the 16 benefits described in paragraphs (a) and (c) of subsection 1.

17 [13.] 14. An insurer must provide an accessible, transparent 18 and expedited process which is not unduly burdensome by which an 19 insured, or the authorized representative of the insured, may request 20 an exception relating to any medical management technique used by 21 the insurer to obtain any benefit required by this section without a 22 higher deductible, copayment or coinsurance.

23

[14.] 15. As used in this section:

(a) "In-network pharmacy" means a pharmacy that has
entered into a contract with an insurer to provide services to
insureds through a network plan offered or issued by the insurer.

(b) "Medical management technique" means a practice which is
used to control the cost or utilization of health care services or
prescription drug use. The term includes, without limitation, the use
of step therapy, prior authorization or categorizing drugs and
devices based on cost, type or method of administration.

32 **[(b)] (c)** "Network plan" means a policy of health insurance 33 offered by an insurer under which the financing and delivery of 34 medical care, including items and services paid for as medical care, 35 are provided, in whole or in part, through a defined set of providers 36 under contract with the insurer. The term does not include an 37 arrangement for the financing of premiums.

38 [(c)] (d) "Provider network contract" means a contract 39 between an insurer and a provider of health care or pharmacy 40 specifying the rights and responsibilities of the insurer and the 41 provider of health care or pharmacy, as applicable, for delivery of 42 health care services pursuant to a network plan.

43 (e) "Provider of health care" has the meaning ascribed to it in 44 NRS 629.031.

45 [(d)] (f) "Therapeutic equivalent" means a drug which:





(1) Contains an identical amount of the same active 1 2 ingredients in the same dosage and method of administration as 3 another drug; (2) Is expected to have the same clinical effect when 4 5 administered to a patient pursuant to a prescription or order as 6 another drug; and 7 (3) Meets any other criteria required by the Food and Drug 8 Administration for classification as a therapeutic equivalent. 9 Sec. 15. NRS 689B.0378 is hereby amended to read as 10 follows: 11 689B.0378 1. Except as otherwise provided in subsection [7] 12 8, an insurer that offers or issues a policy of group health insurance 13 shall include in the policy coverage for: 14 (a) Up to a 12-month supply, per prescription, of any type of 15 drug for contraception or its therapeutic equivalent which is: 16 (1) Lawfully prescribed or ordered; 17 (2) Approved by the Food and Drug Administration; 18 (3) Listed in subsection [11;] 12; and 19 (4) Dispensed in accordance with NRS 639.28075; 20 (b) Any type of device for contraception which is: 21 (1) Lawfully prescribed or ordered; 22 (2) Approved by the Food and Drug Administration; and 23 (3) Listed in subsection [11;] 12; 24 (c) Self-administered hormonal contraceptives dispensed by a 25 pharmacist pursuant to NRS 639.28078; 26 (d) Insertion of a device for contraception or removal of such a 27 device if the device was inserted while the insured was covered by 28 the same policy of group health insurance; 29 (e) Education and counseling relating to the initiation of the use 30 of contraception and any necessary follow-up after initiating such 31 use; 32 (f) Management of side effects relating to contraception; and (g) Voluntary sterilization for women. 33 34 2. An insurer shall provide coverage for any services listed in 35 subsection 1 which are within the authorized scope of practice of a 36 pharmacist when such services are provided by a pharmacist who 37 is employed by or serves as an independent contractor of an in-38 network pharmacy and in accordance with the applicable network contract. Such coverage must be provided to the same extent as if 39 40 the services were provided by another provider of health care, as applicable to the services being provided. The terms of the policy 41 42 *must not limit:* 43 (a) Coverage for services listed in subsection 1 and provided by 44 such a pharmacist to a number of occasions less than the coverage





1 for such services when provided by another provider of health 2 care.

#### 3 (b) Reimbursement for services listed in subsection 1 and 4 provided by such a pharmacist to an amount less than the amount 5 reimbursed for similar services provided by a physician, physician 6 assistant or advanced practice registered nurse.

7 **3.** An insurer must ensure that the benefits required by 8 subsection 1 are made available to an insured through a provider of 9 health care who participates in the network plan of the insurer.

10 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 11 is not available or a provider of health care deems a covered 12 therapeutic equivalent to be medically inappropriate, an alternate 13 therapeutic equivalent prescribed by a provider of health care must 14 be covered by the insurer.

15 [4.] 5. Except as otherwise provided in subsections [9,] 10, 11
16 and [12,] 13, an insurer that offers or issues a policy of group health
17 insurance shall not:

(a) Require an insured to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition to obtain any benefit included in the policy pursuant
to subsection 1;

(b) Refuse to issue a policy of group health insurance or cancel a
policy of group health insurance solely because the person applying
for or covered by the policy uses or may use any such benefit;

(c) Offer or pay any type of material inducement or financial
 incentive to an insured to discourage the insured from obtaining any
 such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an insured, including, without limitation, reducing the
reimbursement to the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
 financial incentive to a provider of health care to deny, reduce,
 withhold, limit or delay access to any such benefit to an insured; or

(f) Impose any other restrictions or delays on the access of an
 insured to any such benefit.

36 [5.] 6. Coverage pursuant to this section for the covered 37 dependent of an insured must be the same as for the insured.

38 [6.] 7. Except as otherwise provided in subsection [7,] 8, a 39 policy subject to the provisions of this chapter that is delivered, 40 issued for delivery or renewed on or after January 1, [2022,] 2024, 41 has the legal effect of including the coverage required by 42 [subsection 1,] this section, and any provision of the policy or the 43 renewal which is in conflict with this section is void.

44 **[7.]** 8. An insurer that offers or issues a policy of group health 45 insurance and which is affiliated with a religious organization is not





required to provide the coverage required by subsection 1 if the
 insurer objects on religious grounds. Such an insurer shall, before
 the issuance of a policy of group health insurance and before the
 renewal of such a policy, provide to the group policyholder or
 prospective insured, as applicable, written notice of the coverage
 that the insurer refuses to provide pursuant to this subsection.

7 [8.] 9. If an insurer refuses, pursuant to subsection [7,] 8, to 8 provide the coverage required by subsection 1, an employer may 9 otherwise provide for the coverage for the employees of the 10 employer.

11 [9.] 10. An insurer may require an insured to pay a higher 12 deductible, copayment or coinsurance for a drug for contraception if 13 the insured refuses to accept a therapeutic equivalent of the drug.

14 [10.] 11. For each of the 18 methods of contraception listed in 15 subsection [11] 12 that have been approved by the Food and Drug 16 Administration, a policy of group health insurance must include at least one drug or device for contraception within each method for 17 18 which no deductible, copayment or coinsurance may be charged to 19 the insured, but the insurer may charge a deductible, copayment or coinsurance for any other drug or device that provides the same 20 21 method of contraception. If the insurer charges a copayment or 22 coinsurance for a drug for contraception, the insurer may only 23 require an insured to pay the copayment or coinsurance:

(a) Once for the entire amount of the drug dispensed for the
 plan year; or

- 26 (b) Once for each 1-month supply of the drug dispensed.
- 27 [11.] 12. The following 18 methods of contraception must be 28 covered pursuant to this section:
- 29 (a) Voluntary sterilization for women;
- 30 (b) Surgical sterilization implants for women;
- 31 (c) Implantable rods;
- 32 (d) Copper-based intrauterine devices;
- 33 (e) Progesterone-based intrauterine devices;
- 34 (f) Injections;
- 35 (g) Combined estrogen- and progestin-based drugs;
- 36 (h) Progestin-based drugs;
- 37 (i) Extended- or continuous-regimen drugs;
- 38 (j) Estrogen- and progestin-based patches;
- 39 (k) Vaginal contraceptive rings;
- 40 (1) Diaphragms with spermicide;
- 41 (m) Sponges with spermicide;
- 42 (n) Cervical caps with spermicide;
- 43 (o) Female condoms;
- 44 (p) Spermicide;





1 (q) Combined estrogen- and progestin-based drugs for 2 emergency contraception or progestin-based drugs for emergency 3 contraception; and

4

(r) Úlipristal acetate for emergency contraception.

5 [12.] 13. Except as otherwise provided in this section and 6 federal law, an insurer may use medical management techniques, 7 including, without limitation, any available clinical evidence, to 8 determine the frequency of or treatment relating to any benefit 9 required by this section or the type of provider of health care to use 10 for such treatment.

11

[13.] 14. An insurer shall not [use] :

(a) Use medical management techniques to require an insured to
 use a method of contraception other than the method prescribed or
 ordered by a provider of health care [.]; or

15 (b) Require an insured to obtain prior authorization for the 16 benefits described in paragraphs (a) and (c) of subsection 1.

17 **[14.]** *15.* An insurer must provide an accessible, transparent 18 and expedited process which is not unduly burdensome by which an 19 insured, or the authorized representative of the insured, may request 20 an exception relating to any medical management technique used by 21 the insurer to obtain any benefit required by this section without a 22 higher deductible, copayment or coinsurance.

23

[15.] 16. As used in this section:

(a) "In-network pharmacy" means a pharmacy that has
entered into a contract with an insurer to provide services to
insureds through a network plan offered or issued by the insurer.

(b) "Medical management technique" means a practice which is
used to control the cost or utilization of health care services or
prescription drug use. The term includes, without limitation, the use
of step therapy, prior authorization or categorizing drugs and
devices based on cost, type or method of administration.

32 **[(b)] (c)** "Network plan" means a policy of group health 33 insurance offered by an insurer under which the financing and 34 delivery of medical care, including items and services paid for as 35 medical care, are provided, in whole or in part, through a defined set 36 of providers under contract with the insurer. The term does not 37 include an arrangement for the financing of premiums.

38 [(c)] (d) "Provider network contract" means a contract 39 between an insurer and a provider of health care or pharmacy 40 specifying the rights and responsibilities of the insurer and the 41 provider of health care or pharmacy, as applicable, for delivery of 42 health care services pursuant to a network plan.

43 (e) "Provider of health care" has the meaning ascribed to it in 44 NRS 629.031.

45 [(d)] (f) "Therapeutic equivalent" means a drug which:





(1) Contains an identical amount of the same active 1 2 ingredients in the same dosage and method of administration as 3 another drug; (2) Is expected to have the same clinical effect when 4 5 administered to a patient pursuant to a prescription or order as 6 another drug; and 7 (3) Meets any other criteria required by the Food and Drug 8 Administration for classification as a therapeutic equivalent. 9 Sec. 16. NRS 689C.1676 is hereby amended to read as 10 follows: 11 689C.1676 1. Except as otherwise provided in subsection [7] 12 8, a carrier that offers or issues a health benefit plan shall include in 13 the plan coverage for: 14 (a) Up to a 12-month supply, per prescription, of any type of 15 drug for contraception or its therapeutic equivalent which is: 16 (1) Lawfully prescribed or ordered; 17 (2) Approved by the Food and Drug Administration; 18 (3) Listed in subsection [10;] 11; and 19 (4) Dispensed in accordance with NRS 639.28075; 20 (b) Any type of device for contraception which is: 21 (1) Lawfully prescribed or ordered; 22 (2) Approved by the Food and Drug Administration; and 23 (3) Listed in subsection [10;] 11; 24 (c) Self-administered hormonal contraceptives dispensed by a 25 pharmacist pursuant to NRS 639.28078; 26 (d) Insertion of a device for contraception or removal of such a 27 device if the device was inserted while the insured was covered by 28 the same health benefit plan; 29 (e) Education and counseling relating to the initiation of the use of contraception and any necessary follow-up after initiating such 30 31 use: 32 (f) Management of side effects relating to contraception; and (g) Voluntary sterilization for women. 33 34 2. A carrier shall provide coverage for any services listed in 35 subsection 1 which are within the authorized scope of practice of a 36 pharmacist when such services are provided by a pharmacist who 37 is employed by or serves as an independent contractor of an in-38 network pharmacy and in accordance with the applicable provider network contract. Such coverage must be provided to the same 39 40 extent as if the services were provided by another provider of health care, as applicable to the services being provided. The terms 41 42 of the policy must not limit: (a) Coverage for services listed in subsection 1 and provided by 43 44 such a pharmacist to a number of occasions less than the coverage





1 for such services when provided by another provider of health 2 care.

#### 3 (b) Reimbursement for services listed in subsection 1 and 4 provided by such a pharmacist to an amount less than the amount 5 reimbursed for similar services provided by a physician, physician 6 assistant or advanced practice registered nurse.

7 **3.** A carrier must ensure that the benefits required by 8 subsection 1 are made available to an insured through a provider of 9 health care who participates in the network plan of the carrier.

10 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 11 is not available or a provider of health care deems a covered 12 therapeutic equivalent to be medically inappropriate, an alternate 13 therapeutic equivalent prescribed by a provider of health care must 14 be covered by the carrier.

15 [4.] 5. Except as otherwise provided in subsections [8,] 9, 10 16 and [11,] 12, a carrier that offers or issues a health benefit plan shall 17 not:

(a) Require an insured to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition to obtain any benefit included in the health benefit
plan pursuant to subsection 1;

(b) Refuse to issue a health benefit plan or cancel a health
benefit plan solely because the person applying for or covered by
the plan uses or may use any such benefit;

(c) Offer or pay any type of material inducement or financial
incentive to an insured to discourage the insured from obtaining any
such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an insured, including, without limitation, reducing the
reimbursement to the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
financial incentive to a provider of health care to deny, reduce,
withhold, limit or delay access to any such benefit to an insured; or

(f) Impose any other restrictions or delays on the access of an
 insured to any such benefit.

36 [5.] 6. Čoverage pursuant to this section for the covered 37 dependent of an insured must be the same as for the insured.

16.] 7. Except as otherwise provided in subsection [7,] 8, a
health benefit plan subject to the provisions of this chapter that is
delivered, issued for delivery or renewed on or after January 1,
[2022,] 2024, has the legal effect of including the coverage required
by [subsection 1,] this section, and any provision of the plan or the
renewal which is in conflict with this section is void.

44 **[7.]** 8. A carrier that offers or issues a health benefit plan and 45 which is affiliated with a religious organization is not required to





1 provide the coverage required by subsection 1 if the carrier objects 2 on religious grounds. Such a carrier shall, before the issuance of a

health benefit plan and before the renewal of such a plan, provide to
the prospective insured written notice of the coverage that the
carrier refuses to provide pursuant to this subsection.

6 [8.] 9. A carrier may require an insured to pay a higher 7 deductible, copayment or coinsurance for a drug for contraception if 8 the insured refuses to accept a therapeutic equivalent of the drug.

9 For each of the 18 methods of contraception listed in <del>[9.]</del> 10. subsection [10] 11 that have been approved by the Food and Drug 10 Administration, a health benefit plan must include at least one drug 11 12 or device for contraception within each method for which no 13 deductible, copayment or coinsurance may be charged to the 14 insured, but the carrier may charge a deductible, copayment or 15 coinsurance for any other drug or device that provides the same 16 method of contraception. If the carrier charges a copayment or 17 coinsurance for a drug for contraception, the carrier may only 18 require an insured to pay the copayment or coinsurance:

19 (a) Once for the entire amount of the drug dispensed for the 20 plan year; or

21 (b) Once for each 1-month supply of the drug dispensed.

22 [10.] 11. The following 18 methods of contraception must be 23 covered pursuant to this section:

- 24 (a) Voluntary sterilization for women;
- 25 (b) Surgical sterilization implants for women;
- 26 (c) Implantable rods;
- 27 (d) Copper-based intrauterine devices;
- 28 (e) Progesterone-based intrauterine devices;
- 29 (f) Injections;
- 30 (g) Combined estrogen- and progestin-based drugs;
- 31 (h) Progestin-based drugs;
- 32 (i) Extended- or continuous-regimen drugs;
- 33 (j) Estrogen- and progestin-based patches;
- 34 (k) Vaginal contraceptive rings;
- 35 (1) Diaphragms with spermicide;
- 36 (m) Sponges with spermicide;
- 37 (n) Cervical caps with spermicide;
- 38 (o) Female condoms;
- 39 (p) Spermicide;

40 (q) Combined estrogen- and progestin-based drugs for 41 emergency contraception or progestin-based drugs for emergency 42 contraception; and

43 (r) Ulipristal acetate for emergency contraception.

44 [11.] 12. Except as otherwise provided in this section and 45 federal law, a carrier may use medical management techniques,





1 including, without limitation, any available clinical evidence, to 2 determine the frequency of or treatment relating to any benefit 3 required by this section or the type of provider of health care to use

4 for such treatment.

5

<del>[12.]</del> **13**. A carrier shall not **[use]**:

6 (a) Use medical management techniques to require an insured to 7 use a method of contraception other than the method prescribed or 8 ordered by a provider of health care [-]; or

9 (b) Require an insured to obtain prior authorization for the 10 benefits described in paragraphs (a) and (c) of subsection 1.

11 [13.] 14. A carrier must provide an accessible, transparent and 12 expedited process which is not unduly burdensome by which an 13 insured, or the authorized representative of the insured, may request 14 an exception relating to any medical management technique used by the carrier to obtain any benefit required by this section without a 15 16 higher deductible, copayment or coinsurance.

17

[14.] 15. As used in this section:

18 (a) "In-network pharmacy" means a pharmacy that has entered into a contract with a carrier to provide services to 19 20 insureds through a network plan offered or issued by the carrier.

21 (b) "Medical management technique" means a practice which is 22 used to control the cost or utilization of health care services or 23 prescription drug use. The term includes, without limitation, the use 24 of step therapy, prior authorization or categorizing drugs and 25 devices based on cost, type or method of administration.

26 (b) (c) "Network plan" means a health benefit plan offered by 27 a carrier under which the financing and delivery of medical care, 28 including items and services paid for as medical care, are provided, 29 in whole or in part, through a defined set of providers under contract 30 with the carrier. The term does not include an arrangement for the 31 financing of premiums.

32 [(c)] (d) "Provider network contract" means a contract between a carrier and a provider of health care or pharmacy 33 specifying the rights and responsibilities of the carrier and the 34 35 provider of health care or pharmacy, as applicable, for delivery of 36 health care services pursuant to a network plan.

37 (e) "Provider of health care" has the meaning ascribed to it in NRS 629.031. 38 39

(f) "Therapeutic equivalent" means a drug which:

40 (1) Contains an identical amount of the same active 41 ingredients in the same dosage and method of administration as 42 another drug:

43 (2) Is expected to have the same clinical effect when 44 administered to a patient pursuant to a prescription or order as 45 another drug; and





2 Administration for classification as a therapeutic equivalent. 3 Sec. 17. NRS 695A.1865 is hereby amended to read as 4 follows: 5 695A.1865 1. Except as otherwise provided in subsection [7] 6 8, a society that offers or issues a benefit contract which provides 7 coverage for prescription drugs or devices shall include in the 8 contract coverage for: 9 (a) Up to a 12-month supply, per prescription, of any type of drug for contraception or its therapeutic equivalent which is: 10 11 (1) Lawfully prescribed or ordered; 12 (2) Approved by the Food and Drug Administration; 13 (3) Listed in subsection [10;] 11; and 14 (4) Dispensed in accordance with NRS 639.28075; 15 (b) Any type of device for contraception which is: 16 (1) Lawfully prescribed or ordered; 17 (2) Approved by the Food and Drug Administration; and 18 (3) Listed in subsection [10;] 11; 19 (c) Self-administered hormonal contraceptives dispensed by a 20 pharmacist pursuant to NRS 639.28078; 21 (d) Insertion of a device for contraception or removal of such a 22 device if the device was inserted while the insured was covered by 23 the same benefit contract: 24 (e) Education and counseling relating to the initiation of the use 25 of contraception and any necessary follow-up after initiating such 26 use: 27 (f) Management of side effects relating to contraception; and 28 (g) Voluntary sterilization for women. 29 2. A society shall provide coverage for any services listed in 30 subsection 1 which are within the authorized scope of practice of a 31 pharmacist when such services are provided by a pharmacist who 32 is employed by or serves as an independent contractor of an in-33 network pharmacy and in accordance with the applicable provider 34 network contract. Such coverage must be provided to the same 35 extent as if the services were provided by another provider of 36 health care, as applicable to the services being provided. The terms 37 of the policy must not limit: 38 (a) Coverage for services listed in subsection 1 and provided by 39 such a pharmacist to a number of occasions less than the coverage 40 for such services when provided by another provider of health 41 care. 42 (b) Reimbursement for services listed in subsection 1 and 43 provided by such a pharmacist to an amount less than the amount 44 reimbursed for similar services provided by a physician, physician 45 assistant or advanced practice registered nurse.



1



(3) Meets any other criteria required by the Food and Drug

**3.** A society must ensure that the benefits required by subsection 1 are made available to an insured through a provider of health care who participates in the network plan of the society.

4 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 5 is not available or a provider of health care deems a covered 6 therapeutic equivalent to be medically inappropriate, an alternate 7 therapeutic equivalent prescribed by a provider of health care must 8 be covered by the society.

9 [4.] 5. Except as otherwise provided in subsections [8,] 9, 10 10 and [11,] 12, a society that offers or issues a benefit contract shall 11 not:

12 (a) Require an insured to pay a higher deductible, any 13 copayment or coinsurance or require a longer waiting period or 14 other condition for coverage for any benefit included in the benefit 15 contract pursuant to subsection 1;

(b) Refuse to issue a benefit contract or cancel a benefit contract
solely because the person applying for or covered by the contract
uses or may use any such benefit;

(c) Offer or pay any type of material inducement or financial
incentive to an insured to discourage the insured from obtaining any
such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an insured, including, without limitation, reducing the
reimbursement to the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
financial incentive to a provider of health care to deny, reduce,
withhold, limit or delay access to any such benefit to an insured; or

(f) Impose any other restrictions or delays on the access of aninsured to any such benefit.

30 **[5.] 6.** Coverage pursuant to this section for the covered dependent of an insured must be the same as for the insured.

32 [6.] 7. Except as otherwise provided in subsection [7,] 8, a
33 benefit contract subject to the provisions of this chapter that is
34 delivered, issued for delivery or renewed on or after January 1,
35 [2022,] 2024, has the legal effect of including the coverage required
36 by [subsection 1,] this section, and any provision of the contract or
37 the renewal which is in conflict with this section is void.

**[7.] 8.** A society that offers or issues a benefit contract and which is affiliated with a religious organization is not required to provide the coverage required by subsection 1 if the society objects on religious grounds. Such a society shall, before the issuance of a benefit contract and before the renewal of such a contract, provide to the prospective insured written notice of the coverage that the society refuses to provide pursuant to this subsection.





1 [8.] 9. A society may require an insured to pay a higher 2 deductible, copayment or coinsurance for a drug for contraception if 3 the insured refuses to accept a therapeutic equivalent of the drug.

4 <del>[9.]</del> 10. For each of the 18 methods of contraception listed in 5 subsection [10] 11 that have been approved by the Food and Drug 6 Administration, a benefit contract must include at least one drug or 7 device for contraception within each method for which no deductible, copayment or coinsurance may be charged to the 8 9 insured, but the society may charge a deductible, copayment or 10 coinsurance for any other drug or device that provides the same 11 method of contraception. If the society charges a copayment or coinsurance for a drug for contraception, the society may only 12

13 require an insured to pay the copayment or coinsurance:

## 14 (a) Once for the entire amount of the drug dispensed for the 15 plan year; or

16 (b) Once for each 1-month supply of the drug dispensed.

- 17 [10.] 11. The following 18 methods of contraception must be 18 covered pursuant to this section:
- 19 (a) Voluntary sterilization for women;
- 20 (b) Surgical sterilization implants for women;
- 21 (c) Implantable rods;
- 22 (d) Copper-based intrauterine devices;
- 23 (e) Progesterone-based intrauterine devices;
- 24 (f) Injections;
- 25 (g) Combined estrogen- and progestin-based drugs;
- 26 (h) Progestin-based drugs;
- 27 (i) Extended- or continuous-regimen drugs;
- 28 (j) Estrogen- and progestin-based patches;
- 29 (k) Vaginal contraceptive rings;
- 30 (1) Diaphragms with spermicide;
- 31 (m) Sponges with spermicide;
- 32 (n) Cervical caps with spermicide;
- 33 (o) Female condoms;
- 34 (p) Spermicide;

(q) Combined estrogen- and progestin-based drugs for
 emergency contraception or progestin-based drugs for emergency
 contraception; and

38 (r) Ulipristal acetate for emergency contraception.

39 [11.] 12. Except as otherwise provided in this section and 40 federal law, a society may use medical management techniques, 41 including, without limitation, any available clinical evidence, to 42 determine the frequency of or treatment relating to any benefit 43 required by this section or the type of provider of health care to use 44 for such treatment.

45 [12.] 13. A society shall not [use] :





1 (a) Use medical management techniques to require an insured to 2 use a method of contraception other than the method prescribed or 3 ordered by a provider of health care [-]; or

(b) Require an insured to obtain prior authorization for the 4 5 benefits described in paragraphs (a) and (c) of subsection 1.

6 [13.] 14. A society must provide an accessible, transparent and 7 expedited process which is not unduly burdensome by which an 8 insured, or the authorized representative of the insured, may request 9 an exception relating to any medical management technique used by 10 the society to obtain any benefit required by this section without a 11 higher deductible, copayment or coinsurance.

12

[14.] 15. As used in this section:

13 (a) "In-network pharmacy" means a pharmacy that has entered into a contract with a society to provide services to 14 15 insureds through a network plan offered or issued by the society.

(b) "Medical management technique" means a practice which is 16 17 used to control the cost or utilization of health care services or prescription drug use. The term includes, without limitation, the use 18 19 of step therapy, prior authorization or categorizing drugs and devices based on cost, type or method of administration. 20

21 (b) (c) "Network plan" means a benefit contract offered by a 22 society under which the financing and delivery of medical care, 23 including items and services paid for as medical care, are provided, 24 in whole or in part, through a defined set of providers under contract 25 with the society. The term does not include an arrangement for the 26 financing of premiums.

27 [(c)] (d) "Provider network contract" means a contract 28 between a society and a provider of health care or pharmacy 29 specifying the rights and responsibilities of the society and the 30 provider of health care or pharmacy, as applicable, for delivery of 31 health care services pursuant to a network plan.

32 (e) "Provider of health care" has the meaning ascribed to it in 33 NRS 629.031. 34

[(d)] (f) "Therapeutic equivalent" means a drug which:

35 (1) Contains an identical amount of the same active 36 ingredients in the same dosage and method of administration as another drug; 37

38 (2) Is expected to have the same clinical effect when 39 administered to a patient pursuant to a prescription or order as 40 another drug; and

41 (3) Meets any other criteria required by the Food and Drug 42 Administration for classification as a therapeutic equivalent.





1 Sec. 18. NRS 695B.1919 is hereby amended to read as 2 follows: 3 695B.1919 1. Except as otherwise provided in subsection [7] 8, an insurer that offers or issues a contract for hospital or medical 4 5 service shall include in the contract coverage for: 6 (a) Up to a 12-month supply, per prescription, of any type of 7 drug for contraception or its therapeutic equivalent which is: 8 (1) Lawfully prescribed or ordered; 9 (2) Approved by the Food and Drug Administration; (3) Listed in subsection [11:] 12; and 10 (4) Dispensed in accordance with NRS 639.28075; 11 12 (b) Any type of device for contraception which is: 13 (1) Lawfully prescribed or ordered; (2) Approved by the Food and Drug Administration; and 14 15 (3) Listed in subsection [11;] 12; 16 (c) Self-administered hormonal contraceptives dispensed by a 17 pharmacist pursuant to NRS 639.28078; 18 (d) Insertion of a device for contraception or removal of such a 19 device if the device was inserted while the insured was covered by 20 the same contract for hospital or medical service; 21 (e) Education and counseling relating to the initiation of the use 22 of contraception and any necessary follow-up after initiating such 23 use: 24 (f) Management of side effects relating to contraception; and 25 (g) Voluntary sterilization for women. 26 An insurer shall provide coverage for any services listed in 2. 27 subsection 1 which are within the authorized scope of practice of a 28 pharmacist when such services are provided by a pharmacist who 29 is employed by or serves as an independent contractor of an innetwork pharmacy and in accordance with the applicable provider 30 31 network contract. Such coverage must be provided to the same 32 extent as if the services were provided by another provider of 33 health care, as applicable to the services being provided. The terms 34 of the policy must not limit: 35 (a) Coverage for services listed in subsection 1 and provided by 36 such a pharmacist to a number of occasions less than the coverage for such services when provided by another provider of health 37 38 care. (b) Reimbursement for services listed in subsection 1 and 39 40 provided by such a pharmacist to an amount less than the amount reimbursed for similar services provided by a physician, physician 41 42 assistant or advanced practice registered nurse. 43 3. An insurer that offers or issues a contract for hospital or 44 medical services must ensure that the benefits required by





subsection 1 are made available to an insured through a provider of
 health care who participates in the network plan of the insurer.

3 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 4 is not available or a provider of health care deems a covered 5 therapeutic equivalent to be medically inappropriate, an alternate 6 therapeutic equivalent prescribed by a provider of health care must 7 be covered by the insurer.

8 [4.] 5. Except as otherwise provided in subsections [9,] 10, 11 9 and [12,] 13, an insurer that offers or issues a contract for hospital or 10 medical service shall not:

(a) Require an insured to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition to obtain any benefit included in the contract for
hospital or medical service pursuant to subsection 1;

15 (b) Refuse to issue a contract for hospital or medical service or 16 cancel a contract for hospital or medical service solely because the 17 person applying for or covered by the contract uses or may use any 18 such benefit;

(c) Offer or pay any type of material inducement or financial
incentive to an insured to discourage the insured from obtaining any
such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an insured, including, without limitation, reducing the
reimbursement to the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
 financial incentive to a provider of health care to deny, reduce,
 withhold, limit or delay access to any such benefit to an insured; or

(f) Impose any other restrictions or delays on the access of aninsured to any such benefit.

30 [5.] 6. Coverage pursuant to this section for the covered 31 dependent of an insured must be the same as for the insured.

32 [6.] 7. Except as otherwise provided in subsection [7,] 8, a 33 contract for hospital or medical service subject to the provisions of 34 this chapter that is delivered, issued for delivery or renewed on or 35 after January 1, [2022,] 2024, has the legal effect of including the 36 coverage required by [subsection 1,] this section, and any provision 37 of the contract or the renewal which is in conflict with this section is 38 void.

39 [7-] 8. An insurer that offers or issues a contract for hospital or 40 medical service and which is affiliated with a religious organization 41 is not required to provide the coverage required by subsection 1 if 42 the insurer objects on religious grounds. Such an insurer shall, 43 before the issuance of a contract for hospital or medical service and 44 before the renewal of such a contract, provide to the prospective





1 insured written notice of the coverage that the insurer refuses to 2 provide pursuant to this subsection.

3 **8.** 9. If an insurer refuses, pursuant to subsection **7.** 8, to 4 provide the coverage required by subsection 1, an employer may 5 otherwise provide for the coverage for the employees of the 6 employer.

7 An insurer may require an insured to pay a higher <del>[9.]</del> 10. 8 deductible, copayment or coinsurance for a drug for contraception if 9 the insured refuses to accept a therapeutic equivalent of the drug.

10 For each of the 18 methods of contraception listed in <del>[10.]</del> **11**. subsection [11] 12 that have been approved by the Food and Drug 11 12 Administration, a contract for hospital or medical service must 13 include at least one drug or device for contraception within each 14 method for which no deductible, copayment or coinsurance may be 15 charged to the insured, but the insurer may charge a deductible, 16 copayment or coinsurance for any other drug or device that provides 17 the same method of contraception. If the insurer charges a copayment or coinsurance for a drug for contraception, the 18 19 insurer may only require an insured to pay the copayment or

- 20 coinsurance:
- 21 (a) Once for the entire amount of the drug dispensed for the 22 plan year; or 23
  - (b) Once for each 1-month supply of the drug dispensed.
- 24 **11.** *12.* The following 18 methods of contraception must be 25 covered pursuant to this section:
- 26 (a) Voluntary sterilization for women;
- 27 (b) Surgical sterilization implants for women;
- 28 (c) Implantable rods;
- 29 (d) Copper-based intrauterine devices;
- 30 (e) Progesterone-based intrauterine devices;
- 31 (f) Injections:
- 32 (g) Combined estrogen- and progestin-based drugs;
- 33 (h) Progestin-based drugs;
- 34 (i) Extended- or continuous-regimen drugs;
- 35 (j) Estrogen- and progestin-based patches;
- 36 (k) Vaginal contraceptive rings;
- 37 (1) Diaphragms with spermicide;
- 38 (m) Sponges with spermicide;
- 39 (n) Cervical caps with spermicide;
- 40 (o) Female condoms;
- 41 (p) Spermicide;

42 (q) Combined estrogenand progestin-based drugs for 43 emergency contraception or progestin-based drugs for emergency 44 contraception; and

45 (r) Ulipristal acetate for emergency contraception.





1 [12.] 13. Except as otherwise provided in this section and 2 federal law, an insurer that offers or issues a contract for hospital or 3 medical services may use medical management techniques, 4 including, without limitation, any available clinical evidence, to 5 determine the frequency of or treatment relating to any benefit 6 required by this section or the type of provider of health care to use 7 for such treatment.

8

[13.] 14. An insurer shall not [use] :

9 (a) Use medical management techniques to require an insured to 10 use a method of contraception other than the method prescribed or 11 ordered by a provider of health care [-]; or

12 (b) Require an insured to obtain prior authorization for the 13 benefits described in paragraphs (a) and (c) of subsection 1.

14 **[14.]** *15.* An insurer must provide an accessible, transparent 15 and expedited process which is not unduly burdensome by which an 16 insured, or the authorized representative of the insured, may request 17 an exception relating to any medical management technique used by 18 the insurer to obtain any benefit required by this section without a 19 higher deductible, copayment or coinsurance.

20

[15.] 16. As used in this section:

(a) "In-network pharmacy" means a pharmacy that has
entered into a contract with an insurer to provide services to
insureds through a network plan offered or issued by the insurer.

(b) "Medical management technique" means a practice which is
used to control the cost or utilization of health care services or
prescription drug use. The term includes, without limitation, the use
of step therapy, prior authorization or categorizing drugs and
devices based on cost, type or method of administration.

29 **[(b)] (c)** "Network plan" means a contract for hospital or 30 medical service offered by an insurer under which the financing and 31 delivery of medical care, including items and services paid for as 32 medical care, are provided, in whole or in part, through a defined set 33 of providers under contract with the insurer. The term does not 34 include an arrangement for the financing of premiums.

35 [(c)] (d) "Provider network contract" means a contract 36 between an insurer and a provider of health care or pharmacy 37 specifying the rights and responsibilities of the insurer and the 38 provider of health care or pharmacy, as applicable, for delivery of 39 health care services pursuant to a network plan.

40 (e) "Provider of health care" has the meaning ascribed to it in 41 NRS 629.031.

[(d)] (f) "Therapeutic equivalent" means a drug which:

43 (1) Contains an identical amount of the same active 44 ingredients in the same dosage and method of administration as 45 another drug;



42



1 (2) Is expected to have the same clinical effect when 2 administered to a patient pursuant to a prescription or order as 3 another drug; and (3) Meets any other criteria required by the Food and Drug 4 5 Administration for classification as a therapeutic equivalent. 6 Sec. 19. NRS 695C.1696 is hereby amended to read as 7 follows: 8 695C.1696 1. Except as otherwise provided in subsection [7] 9 8, a health maintenance organization that offers or issues a health care plan shall include in the plan coverage for: 10 (a) Up to a 12-month supply, per prescription, of any type of 11 12 drug for contraception or its therapeutic equivalent which is: 13 (1) Lawfully prescribed or ordered; (2) Approved by the Food and Drug Administration: 14 15 (3) Listed in subsection [11;] 12; and 16 (4) Dispensed in accordance with NRS 639.28075; 17 (b) Any type of device for contraception which is: 18 (1) Lawfully prescribed or ordered; 19 (2) Approved by the Food and Drug Administration; and 20 (3) Listed in subsection [11;] 12; 21 (c) Self-administered hormonal contraceptives dispensed by a 22 pharmacist pursuant to NRS 639.28078; 23 (d) Insertion of a device for contraception or removal of such a 24 device if the device was inserted while the enrollee was covered by 25 the same health care plan; 26 (e) Education and counseling relating to the initiation of the use 27 of contraception and any necessary follow-up after initiating such 28 use: 29 (f) Management of side effects relating to contraception; and 30 (g) Voluntary sterilization for women. 31 2. A health maintenance organization shall provide coverage 32 for any services listed in subsection 1 which are within the 33 authorized scope of practice of a pharmacist when such services are provided by a pharmacist who is employed by or serves as an 34 35 independent contractor of an in-network pharmacy and in accordance with the applicable provider network contract. Such 36 coverage must be provided to the same extent as if the services 37 38 were provided by another provider of health care, as applicable to the services being provided. The terms of the policy must not limit: 39 40 (a) Coverage for services listed in subsection 1 and provided by such a pharmacist to a number of occasions less than the coverage 41 42 for such services when provided by another provider of health 43 care. 44 (b) Reimbursement for services listed in subsection 1 and 45 provided by such a pharmacist to an amount less than the amount





1 reimbursed for similar services provided by a physician, physician 2 assistant or advanced practice registered nurse.

3 **3.** A health maintenance organization must ensure that the 4 benefits required by subsection 1 are made available to an enrollee 5 through a provider of health care who participates in the network 6 plan of the health maintenance organization.

7 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 8 is not available or a provider of health care deems a covered 9 therapeutic equivalent to be medically inappropriate, an alternate 10 therapeutic equivalent prescribed by a provider of health care must 11 be covered by the health maintenance organization.

12 [4.] 5. Except as otherwise provided in subsections [9,] 10, 11 13 and [12,] 13, a health maintenance organization that offers or issues 14 a health care plan shall not:

(a) Require an enrollee to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition to obtain any benefit included in the health care plan
pursuant to subsection 1;

(b) Refuse to issue a health care plan or cancel a health care plan
solely because the person applying for or covered by the plan uses
or may use any such benefit;

(c) Offer or pay any type of material inducement or financial
 incentive to an enrollee to discourage the enrollee from obtaining
 any such benefit;

(d) Penalize a provider of health care who provides any such
benefit to an enrollee, including, without limitation, reducing the
reimbursement of the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
financial incentive to a provider of health care to deny, reduce,
withhold, limit or delay access to any such benefit to an enrollee; or

31 (f) Impose any other restrictions or delays on the access of an 32 enrollee to any such benefit.

33 [5.] 6. Coverage pursuant to this section for the covered 34 dependent of an enrollee must be the same as for the enrollee.

[6.] 7. Except as otherwise provided in subsection [7,] 8, a
health care plan subject to the provisions of this chapter that is
delivered, issued for delivery or renewed on or after January 1,
[2022,] 2024, has the legal effect of including the coverage required
by [subsection 1,] this section, and any provision of the plan or the
renewal which is in conflict with this section is void.

41 **[7.]** 8. A health maintenance organization that offers or issues 42 a health care plan and which is affiliated with a religious 43 organization is not required to provide the coverage required by 44 subsection 1 if the health maintenance organization objects on 45 religious grounds. Such an organization shall, before the issuance of





a health care plan and before the renewal of such a plan, provide to
the prospective enrollee written notice of the coverage that the
health maintenance organization refuses to provide pursuant to this
subsection.

5 [8.] 9. If a health maintenance organization refuses, pursuant 6 to subsection [7,] 8, to provide the coverage required by subsection 7 1, an employer may otherwise provide for the coverage for the 8 employees of the employer.

9 [9.] 10. A health maintenance organization may require an 10 enrollee to pay a higher deductible, copayment or coinsurance for a 11 drug for contraception if the enrollee refuses to accept a therapeutic 12 equivalent of the drug.

13 [10.] 11. For each of the 18 methods of contraception listed in 14 subsection [11] 12 that have been approved by the Food and Drug 15 Administration, a health care plan must include at least one drug or 16 device for contraception within each method for which no 17 deductible, copayment or coinsurance may be charged to the enrollee, but the health maintenance organization may charge a 18 19 deductible, copayment or coinsurance for any other drug or device 20 that provides the same method of contraception. If the health 21 maintenance organization charges a copayment or coinsurance 22 for a drug for contraception, the health maintenance organization 23 may only require an enrollee to pay the copayment or 24 coinsurance:

25 (a) Once for the entire amount of the drug dispensed for the 26 plan year; or

# (b) Once for each 1-month supply of the drug dispensed.

28 [11.] 12. The following 18 methods of contraception must be 29 covered pursuant to this section:

- 30 (a) Voluntary sterilization for women;
- 31 (b) Surgical sterilization implants for women;
- 32 (c) Implantable rods;
- 33 (d) Copper-based intrauterine devices;
- 34 (e) Progesterone-based intrauterine devices;
- 35 (f) Injections;

27

- 36 (g) Combined estrogen- and progestin-based drugs;
- 37 (h) Progestin-based drugs;
- 38 (i) Extended- or continuous-regimen drugs;
- 39 (j) Estrogen- and progestin-based patches;
- 40 (k) Vaginal contraceptive rings;
- 41 (1) Diaphragms with spermicide;
- 42 (m) Sponges with spermicide;
- 43 (n) Cervical caps with spermicide;
- 44 (o) Female condoms;
- 45 (p) Spermicide;





1 (q) Combined estrogen- and progestin-based drugs for 2 emergency contraception or progestin-based drugs for emergency 3 contraception; and

4

(r) Ulipristal acetate for emergency contraception.

5 [12.] 13. Except as otherwise provided in this section and 6 federal law, a health maintenance organization may use medical 7 management techniques, including, without limitation, any available 8 clinical evidence, to determine the frequency of or treatment relating 9 to any benefit required by this section or the type of provider of 10 health care to use for such treatment.

11

[13.] 14. A health maintenance organization shall not [use] :

(a) Use medical management techniques to require an enrollee
 to use a method of contraception other than the method prescribed
 or ordered by a provider of health care [-]; or

15 (b) Require an enrollee to obtain prior authorization for the 16 benefits described in paragraphs (a) and (c) of subsection 1.

17 **[14.]** *15.* A health maintenance organization must provide an 18 accessible, transparent and expedited process which is not unduly 19 burdensome by which an enrollee, or the authorized representative 20 of the enrollee, may request an exception relating to any medical 21 management technique used by the health maintenance organization 22 to obtain any benefit required by this section without a higher 23 deductible, copayment or coinsurance.

24 [15.]

[15.] 16. As used in this section:

(a) "In-network pharmacy" means a pharmacy that has
entered into a contract with a health maintenance organization to
provide services to enrollees through a network plan offered or
issued by the health maintenance organization.

(b) "Medical management technique" means a practice which is
 used to control the cost or utilization of health care services or
 prescription drug use. The term includes, without limitation, the use
 of step therapy, prior authorization or categorizing drugs and
 devices based on cost, type or method of administration.

(b) (c) "Network plan" means a health care plan offered by a 34 35 health maintenance organization under which the financing and delivery of medical care, including items and services paid for as 36 medical care, are provided, in whole or in part, through a defined set 37 38 of providers under contract with the health maintenance 39 organization. The term does not include an arrangement for the 40 financing of premiums.

41 [(c)] (d) "Provider network contract" means a contract 42 between a health maintenance organization and a provider of

43 health care or pharmacy specifying the rights and responsibilities

44 of the health maintenance organization and the provider of health





care or pharmacy, as applicable, for delivery of health care 1 2 services pursuant to a network plan. 3 (e) "Provider of health care" has the meaning ascribed to it in NRS 629.031. 4 [(d)] (f) "Therapeutic equivalent" means a drug which: 5 6 (1) Contains an identical amount of the same active 7 ingredients in the same dosage and method of administration as 8 another drug; 9 (2) Is expected to have the same clinical effect when administered to a patient pursuant to a prescription or order as 10 11 another drug; and 12 (3) Meets any other criteria required by the Food and Drug 13 Administration for classification as a therapeutic equivalent. 14 Sec. 20. NRS 695G.1715 is hereby amended to read as 15 follows: 16 695G.1715 1. Except as otherwise provided in subsection [7,]17 8, a managed care organization that offers or issues a health care 18 plan shall include in the plan coverage for: 19 (a) Up to a 12-month supply, per prescription, of any type of 20 drug for contraception or its therapeutic equivalent which is: 21 (1) Lawfully prescribed or ordered; 22 (2) Approved by the Food and Drug Administration; 23 (3) Listed in subsection [10;] 11; and 24 (4) Dispensed in accordance with NRS 639.28075: 25 (b) Any type of device for contraception which is: 26 (1) Lawfully prescribed or ordered; 27 (2) Approved by the Food and Drug Administration; and 28 (3) Listed in subsection [10;] 11; 29 (c) Self-administered hormonal contraceptives dispenses by a 30 pharmacist pursuant to NRS 639.28078; (d) Insertion of a device for contraception or removal of such a 31 32 device if the device was inserted while the insured was covered by 33 the same health care plan: 34 (e) Education and counseling relating to the initiation of the use 35 of contraception and any necessary follow-up after initiating such 36 use: 37 (f) Management of side effects relating to contraception; and 38 (g) Voluntary sterilization for women. 39 2. A managed care organization shall provide coverage for 40 any services listed in subsection 1 which are within the authorized 41 scope of practice of a pharmacist when such services are provided 42 by a pharmacist who is employed by or serves as an independent 43 contractor of an in-network pharmacy and in accordance with the 44 applicable provider network contract. Such coverage must be 45 provided to the same extent as if the services were provided by





another provider of health care, as applicable to the services being
 provided. The terms of the policy must not limit:

(a) Coverage for services listed in subsection 1 and provided by
such a pharmacist to a number of occasions less than the coverage
for such services when provided by another provider of health
care.

7 (b) Reimbursement for services listed in subsection 1 and 8 provided by such a pharmacist to an amount less than the amount 9 reimbursed for similar services provided by a physician, physician 10 assistant or advanced practice registered nurse.

**3.** A managed care organization must ensure that the benefits required by subsection 1 are made available to an insured through a provider of health care who participates in the network plan of the managed care organization.

15 [3.] 4. If a covered therapeutic equivalent listed in subsection 1 16 is not available or a provider of health care deems a covered 17 therapeutic equivalent to be medically inappropriate, an alternate 18 therapeutic equivalent prescribed by a provider of health care must 19 be covered by the managed care organization.

20 [4.] 5. Except as otherwise provided in subsections [8,] 9, 10 21 and [11,] 12, a managed care organization that offers or issues a 22 health care plan shall not:

(a) Require an insured to pay a higher deductible, any
copayment or coinsurance or require a longer waiting period or
other condition to obtain any benefit included in the health care plan
pursuant to subsection 1;

(b) Refuse to issue a health care plan or cancel a health care plan
solely because the person applying for or covered by the plan uses
or may use any such benefits;

30 (c) Offer or pay any type of material inducement or financial
 31 incentive to an insured to discourage the insured from obtaining any
 32 such benefits;

(d) Penalize a provider of health care who provides any such
benefits to an insured, including, without limitation, reducing the
reimbursement of the provider of health care;

(e) Offer or pay any type of material inducement, bonus or other
financial incentive to a provider of health care to deny, reduce,
withhold, limit or delay access to any such benefits to an insured; or
(f) Impose any other restrictions or delays on the access of an

(f) Impose any other restrictions or delays on the access of aninsured to any such benefits.

41 **[5.] 6.** Coverage pursuant to this section for the covered 42 dependent of an insured must be the same as for the insured.

43 [6.] 7. Except as otherwise provided in subsection [7,] 8, a 44 health care plan subject to the provisions of this chapter that is 45 delivered, issued for delivery or renewed on or after January 1,





[2022,] 2024, has the legal effect of including the coverage required
 by [subsection 1,] this section, and any provision of the plan or the
 renewal which is in conflict with this section is void.

4 **7.** 8. A managed care organization that offers or issues a 5 health care plan and which is affiliated with a religious organization 6 is not required to provide the coverage required by subsection 1 if 7 the managed care organization objects on religious grounds. Such an 8 organization shall, before the issuance of a health care plan and before the renewal of such a plan, provide to the prospective insured 9 10 written notice of the coverage that the managed care organization 11 refuses to provide pursuant to this subsection.

12 [8.] 9. A managed care organization may require an insured to 13 pay a higher deductible, copayment or coinsurance for a drug for 14 contraception if the insured refuses to accept a therapeutic 15 equivalent of the drug.

16 **9. 10.** For each of the 18 methods of contraception listed in 17 subsection [10] 11 that have been approved by the Food and Drug 18 Administration, a health care plan must include at least one drug or 19 device for contraception within each method for which no 20 deductible, copayment or coinsurance may be charged to the 21 insured, but the managed care organization may charge a deductible, 22 copayment or coinsurance for any other drug or device that provides 23 the same method of contraception. If the managed care 24 organization charges a copayment or coinsurance for a drug for contraception, the managed care organization may only require 25 26 an enrollee to pay the copayment or coinsurance:

27 (a) Once for the entire amount of the drug dispensed for the 28 plan year; or

 $(\check{b})$  Once for each 1-month supply of the drug dispensed.

30 [10.] 11. The following 18 methods of contraception must be 31 covered pursuant to this section:

- 32 (a) Voluntary sterilization for women;
- 33 (b) Surgical sterilization implants for women;
- 34 (c) Implantable rods;
- 35 (d) Copper-based intrauterine devices;
- 36 (e) Progesterone-based intrauterine devices;
- 37 (f) Injections;

29

- 38 (g) Combined estrogen- and progestin-based drugs;
- 39 (h) Progestin-based drugs;
- 40 (i) Extended- or continuous-regimen drugs;
- 41 (j) Estrogen- and progestin-based patches;
- 42 (k) Vaginal contraceptive rings;
- 43 (1) Diaphragms with spermicide;
- 44 (m) Sponges with spermicide;
- 45 (n) Cervical caps with spermicide;





1 (o) Female condoms;

(p) Spermicide;

3 (q) Combined estrogen- and progestin-based drugs for 4 emergency contraception or progestin-based drugs for emergency 5 contraception; and

(r) Ulipristal acetate for emergency contraception.

7 [11.] 12. Except as otherwise provided in this section and 8 federal law, a managed care organization may use medical 9 management techniques, including, without limitation, any available 10 clinical evidence, to determine the frequency of or treatment relating 11 to any benefit required by this section or the type of provider of 12 health care to use for such treatment.

13

2

6

[12.] 13. A managed care organization shall not [use] :

(a) Use medical management techniques to require an insured to
 use a method of contraception other than the method prescribed or
 ordered by a provider of health care [.]; or

17 (b) Require an insured to obtain prior authorization for the 18 benefits described in paragraphs (a) and (c) of subsection 1.

19 **[13.]** 14. A managed care organization must provide an accessible, transparent and expedited process which is not unduly burdensome by which an insured, or the authorized representative of the insured, may request an exception relating to any medical management technique used by the managed care organization to obtain any benefit required by this section without a higher deductible, copayment or coinsurance.

26

[14.] 15. As used in this section:

27 (a) "In-network pharmacy" means a pharmacy that has 28 entered into a contract with a managed care organization to 29 provide services to insureds through a network plan offered or 30 issued by the managed care organization.

(b) "Medical management technique" means a practice which is
used to control the cost or utilization of health care services or
prescription drug use. The term includes, without limitation, the use
of step therapy, prior authorization or categorizing drugs and
devices based on cost, type or method of administration.

36 [(b)] (c) "Network plan" means a health care plan offered by a 37 managed care organization under which the financing and delivery 38 of medical care, including items and services paid for as medical 39 care, are provided, in whole or in part, through a defined set of 40 providers under contract with the managed care organization. The 41 term does not include an arrangement for the financing of 42 premiums.

43 [(c)] (d) "Provider network contract" means a contract 44 between a managed care organization and a provider of health 45 care or pharmacy specifying the rights and responsibilities of the





1 managed care organization and the provider of health care or 2 pharmacy, as applicable, for delivery of health care services

3 pursuant to a network plan.

4 (e) "Provider of health care" has the meaning ascribed to it in 5 NRS 629.031.

6

[(d)] (f) "Therapeutic equivalent" means a drug which:

7 (1) Contains an identical amount of the same active 8 ingredients in the same dosage and method of administration as 9 another drug;

10 (2) Is expected to have the same clinical effect when 11 administered to a patient pursuant to a prescription or order as 12 another drug; and

(3) Meets any other criteria required by the Food and DrugAdministration for classification as a therapeutic equivalent.

**Sec. 21.** 1. The provisions of NRS 422.4053, as amended by section 2 of this act, do not apply to a contract between the Department of Health and Human Services and a pharmacy benefit manager or a health maintenance organization entered into pursuant to NRS 422.4053 before January 1, 2024, but do apply to any renewal or extension of such a contract.

21 2. As used in this section:

(a) "Health maintenance organization" has the meaning ascribedto it in NRS 695C.030.

(b) "Pharmacy benefit manager" has the meaning ascribed to itin NRS 683A.174.

26 Sec. 22. The provisions of NRS 354.599 do not apply to any 27 additional expenses of a local government that are related to the 28 provisions of this act.

29 Sec. 23. 1. This section and sections 4 and 5 of this act 30 become effective upon passage and approval.

2. Sections 1, 2, 3 and 6 to 22, inclusive, of this act become effective:

(a) Upon passage and approval for the purpose of performing
 any preparatory administrative tasks that are necessary to carry out
 the provisions of this act; and

36 (b) On January 1, 2024, for all other purposes.





